

## Aberystwyth University

### *Arginine Citrullination at the C-Terminal Domain Controls RNA Polymerase II Transcription*

Sharma, Priyanka; Lioutas, Antonios; Fernandez-Fuentes, Narcis; Quilez, Javier; Carbonell-Caballero, José; Wright, Roni H. G.; Di Vona, Chiara; Le Dily, François; Schüller, Roland; Eick, Dirk; Oliva, Baldomero

*Published in:*  
Molecular Cell

*DOI:*  
[10.1016/j.molcel.2018.10.016](https://doi.org/10.1016/j.molcel.2018.10.016)

*Publication date:*  
2019

*Citation for published version (APA):*

Sharma, P., Lioutas, A., Fernandez-Fuentes, N., Quilez, J., Carbonell-Caballero, J., Wright, R. H. G., Di Vona, C., Le Dily, F., Schüller, R., Eick, D., & Oliva, B. (2019). Arginine Citrullination at the C-Terminal Domain Controls RNA Polymerase II Transcription. *Molecular Cell*, 73(1), 84-96.  
<https://doi.org/10.1016/j.molcel.2018.10.016>

#### **Document License** CC BY-NC-ND

#### **General rights**

Copyright and moral rights for the publications made accessible in the Aberystwyth Research Portal (the Institutional Repository) are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the Aberystwyth Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the Aberystwyth Research Portal

#### **Take down policy**

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

tel: +44 1970 62 2400  
email: [is@aber.ac.uk](mailto:is@aber.ac.uk)

# Arginine citrullination at the C-terminal domain controls RNA polymerase II transcription

Priyanka Sharma,<sup>1</sup>; Antonios Lioutas,<sup>1</sup>; Narcis Fernandez-Fuentes<sup>2</sup>; Javier Quilez,<sup>1</sup>;  
José Carbonell-Caballero,<sup>1</sup>; Roni H.G. Wright,<sup>1</sup>; Chiara Di Vona,<sup>1</sup>; François Le Dily<sup>1</sup>;  
Roland Schüller,<sup>3</sup>; Dirk Eick,<sup>3</sup>; Baldomero Oliva,<sup>4,5</sup>; Miguel Beato, <sup>\*1,4</sup>

<sup>1</sup>Gene Regulation, Stem Cells and Cancer Program, Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology (BIST), Dr. Aiguader 88, 08003 Barcelona, Spain.

<sup>2</sup>Institute of Biological, Environmental and Rural Science, Aberystwyth University, SY23 3EB Aberystwyth, U.K.

<sup>3</sup>Department of Molecular Epigenetics, Helmholtz Center Munich, Center of Integrated Protein Science, Munich, Germany.

<sup>4</sup>Universitat Pompeu Fabra (UPF), Barcelona, Spain.

<sup>5</sup>Structural Bioinformatics Laboratory (GRIB-IMIM), Department of Experimental and Health Sciences, Barcelona E-08003, Spain.

Correspondence to: [miguelbeato@crg.eu](mailto:miguelbeato@crg.eu)

## SUMMARY

The post-translational modification of key residues at the carboxy-terminal domain of RNA polymerase II (RNAP2-CTD), coordinates transcription, splicing, and RNA processing by modulating its capacity to act as a landing platform for a variety of protein complexes. Here, we identify a new modification at the CTD, the deimination of arginine and its conversion to citrulline by peptidyl arginine deiminase 2 (PADI2), an enzyme that has been associated with several diseases including cancer. We show that among PADI family members, only PADI2 citrullinates R1810 (Cit1810) at repeat 31 of the CTD. Depletion of PADI2 or loss of R1810 result in accumulation of RNAP2 at transcription start sites, reduced gene expression and inhibition of cell proliferation. Cit1810 is needed for interaction with the P-TEFb (positive transcription elongation factor b) kinase complex and for its recruitment to chromatin. In this way, **CTD-Cit1810 favors RNAP2 pause release and efficient transcription in breast cancer cells.**

150 words

**KEYWORDS:** RNA Polymerase II CTD, Citrullination, PADI2, Arginine1810, Breast Cancer cells, Proximal promoter pausing, Cell proliferation.

## INTRODUCTION

In mammals, the RNA polymerase II carboxy-terminal domain (RNAP2-CTD) comprises 52 heptapeptide repeats, the first half of which (1-27) exhibit the consensus repeat sequence  $Y_1S_2P_3T_4S_5P_6S_7$ , whereas the second half (28-52) contains deviations from this consensus (Buratowski et al., 2009; Corden et al., 2013). Post-translational modification of the key residues at RNAP2-CTD dictate recruitment of protein complexes, **that influence transcription elongation and the processing of the nascent transcripts** (Jeronimo et al., 2016; Saldi et al., 2016; Harlen et al., 2017). The CTD is evolutionary conserved and dynamic phosphorylation of  $Y_1$ ,  $S_2$ ,  $T_4$ ,  $S_5$ , and  $S_7$  mediates selective recruitment of protein complexes that modulate various phases of transcription (Eick et al., 2013; Zaborowska et al., 2016; Shah et al., 2018). Systematic studies using genetics and proteomics showed that phosphorylation of  $S_5$  and  $S_2$  is the most frequent modification and contributes to transcription efficiency (Schüller et al., 2016; Corden, 2016). However, modifications in non-consensus repeats have expanded the functional role of the CTD code (Voss et al., 2015; Dias et al., 2015) and recent work has focused on methylation of arginine 1810 (R1810) at repeat 31. Its asymmetrical dimethylation (me2a) by the methyltransferase CARM1 (or PRMT4) inhibits the expression of small nuclear RNAs (snRNAs) and nucleolar RNA (snoRNA) genes in human cells (Sims et al., 2011). This reaction is inhibited by phosphorylation of CTD serine residues, suggesting that it occurs before transcription initiation. In contrast, symmetric dimethylation (me2s) of R1810 by PRMT5 leads to recruitment of the survival of motor neuron protein (SMN) and to the interaction with **senataxin, that enhances transcriptional termination** (Zhao et al., 2016). The functional significance of dynamic post-translational deimination of arginine residues in pathophysiological conditions (Slade et al., 2014; Tanikawa et al., 2018) prompted us to investigate whether this modification occurs at R1810 of RNAP2-CTD and its possible implication in transcription regulation.

Citrullination is a deimination of protein-embedded arginine, which is converted

to the **non-coded** amino acid citrulline (Van et al., 2000; Fuhrmann et al., 2015). Citrullination leads to a reduction in hydrogen-bond formation, affects histone-DNA interactions and influences the chromatin organization. Citrullination also increases the hydrophobicity of proteins that affect the protein folding ability and therefore the functional activity of proteins (Vossenaar et al., 2003; Tanikawa et al., 2018). This reaction is catalyzed by enzymes called peptidyl arginine deiminases (PADIs), which have been associated with diverse disease conditions such as thrombosis, prion disease, neurological disorders, autoimmune disease and cancer (Witalison et al., 2015; Gyorgy et al., 2006; Vossenaar et al., 2003; Baka et al., 2012). Among PADI family members, PADI2 is the most widely expressed isoform and is also overexpressed in breast cancer, where it regulates mammary carcinoma cell migration (Mohan et al., 2012; Cherrington et al., 2012; Horibata et al., 2017). Citrullination of core histones has been related to the gene expression, DNA damage responses and pluripotency (Sharma et al., 2012; Tanikawa et al., 2012; Christophorou et al., 2014), although the underlying mechanisms are largely unknown.

RNAP2-mediated gene expression starts with binding to the gene promoters of basal transcription factors that recruit RNAP2 to form the transcription pre-initiation complex. Shortly after transcription initiation, **RNAP2 pauses 30-50bp downstream of the transcription start sites (TSS), and requires the activation of P-TEFb** (positive transcription elongation factor b) kinase complexes to continue with the productive elongation (Marshall et al., 1995; Adelman et al., 2012; Jonkers et al., 2015 ). Promoter-proximal pausing affects the expression of many genes but is more prominent for highly expressed genes in responses to developmental and environmental stimuli (Zeitlinger et al., 2007; Core et al., 2008; Gilchrist et al., 2010; Day et al., 2016). Recently, RNAP2 pausing was found to inhibit transcriptional initiation, indicating that paused RNAP2 first needs to be released in order to allow a new cycle of transcription initiation (Shao et al., 2017; Gressel et al., 2017). However, despite the strong evidence of RNAP2 pausing, the nature of paused RNAP2 to allow efficient transcription still remains unclear.

Here, we report the discovery that PADI2 citrullinates the R1810 (cit1810) at RNAP2-CTD. The absence of PADI2 mediated cit1810 widely affects transcription and cell proliferation in breast cancer cells. PADI2 occupancy increases with the level of gene transcription. Further, we found that replacing wild-type RNAP2 with the R1810A

mutant compromises transcription, reduces interaction with the P-TEFb complex and leads to accumulation of RNAP2 on the proximal promoter of PADI2 dependent genes. Thus, citrullination of R1810 facilitates interaction with the P-TEFb complex favoring RNAP2 pause release and promoting transcription of cell cycle genes and cell proliferation of breast cancer cells.

## RESULTS

### Citrullination of R1810 at RNAP2-CTD

Two arginine residues within non-consensus repeats in human RNAP2-CTD, R1603 and R1810, are conserved in vertebrates. Recently, R1810 within repeat 31 was found to be asymmetrically (Sims et al., 2011) or symmetrically (Zhao et al., 2016) dimethylated, leading to either reduced expression of snRNAs and snoRNA or to efficient transcription termination, respectively. To examine the possibility that R1810 at RNAP2-CTD could be citrullinated in cells, we immunoprecipitated nuclear extracts from the luminal breast cancer cell line T47D (Truss et al., 1995) with a citrulline antibody followed by western blot with an antibody to RNAP2. We found two specific bands migrating as the non-phosphorylated (IIA) and phosphorylated (IIO) forms of the large subunit POLR2A of RNAP2. The IIO band reacted preferentially with  $\alpha$ -citrulline compared to the IIA band of RNAP2 (**Figure S1A**). We raised a polyclonal antibody against a 13 residues peptide centered on R1810, which was replaced by citrulline (**Figure 1A top**). This antibody ( $\alpha$ -Cit1810) was specific, as it reacted with the citrullinated peptide, but not with the wild-type, methylated (me2aR1810) or phosphorylated (S2 or S5) peptides (**Figure S1B-C**) and mainly recognized the phosphorylated form of RNAP2 in western blots of nuclear extracts from T47D cells (**Figure 1A, Figure S1D**).

To validate that R1810 is citrullinated, we transiently transfected T47D cells with an  $\alpha$ -amanitin resistant HA-tagged wild-type (WT<sup>r</sup>) RNAP2 or with a R1810A<sup>r</sup> mutant of RNAP2, followed by  $\alpha$ -amanitin treatment to deplete the endogenous RNAP2 (**Figure S1 E-G**). Precipitation with anti-HA antibody followed by western blot showed that the WT<sup>r</sup> RNAP2, but not the R1810A<sup>r</sup> mutant, reacts with  $\alpha$ -Cit1810 (**Figure 1B**).

In super-resolution immunofluorescence images of T47D cells,  $\alpha$ -Cit1810 decorated bright clusters overlapping with RNAP2, preferentially in its S2 or S5 phosphorylated forms (**Figure 1C-D**). Thus, R1810 is citrullinated in cells prevalently on the phosphorylated actively transcribing form of RNAP2.

### **Citrullination of R1810 by PADI2**

In a search for the responsible enzyme, we found that T47D cells express only *PADI2* and *PADI3* (**Figure 2A**) among family members. Depletion of PADI2 but not PADI3 reduces R1810 citrullination (**Figure 2B, Figure S2A-B**). In MCF7 breast cancer cells that express *PADI2* and *PADI4* (Cuthbert et al., 2004; Sharma et al., 2012), depletion of *PADI2* but not PADI4 reduced R1810 citrullination (**Figure S2C-D**). To test whether PADI2 acts directly on the RNAP2-CTD we incubated recombinant PADI2 with either a recombinant GST-N-CTD (repeat 1-25.5, including R1603) or with GST-C-CTD (repeat 27-52, including R1810) (**Figure 2C, left panel**). PADI2 citrullinates R1810 in the C-CTD much more efficiently than R1603 in N-CTD (**Figure 2C, right panel**). Thus, PADI2 is the enzyme responsible for citrullination of R1810 in breast cancer cells.

The affinity of PADI2 for the unmodified R1810 peptide measured by microscale thermophoresis (Jerabek et al., 2011) is  $K_d=220\pm54.5$  nM, whereas peptides phosphorylated at S2 or S5 were not bound (**Figure 2D**), suggesting that the observed S2/S5 phosphorylation in R1810 citrullinated CTD most probably occur outside of repeats 31 and 32. In co-immunoprecipitation experiments using T47D and MCF7 cells extracts, PADI2 but neither PADI3 or nor PADI4 interacted with RNAP2 (**Figure S2E-F**). Similarly, an antibody against PADI2 precipitated Cit1810-RNAP2, along with S5P- and S2P-RNAP2 (**Figure 2E, Figure S2G**). Monoclonal antibodies against RNAP2 phosphorylated at S2 and S5 (see methods) precipitated Cit1810 RNAP2 as well as PADI2 but not PADI3 (**Figure 2F**). In T47D nuclear extracts fractionated using size exclusion chromatography PADI2 eluted along with phosphorylated RNAP2 in the high molecular weight fractions, whereas PADI3 eluted in lower molecular weight range (**Figure S2H**). Finally, triple labeling immunofluorescence microscopy showed that PADI2 co-localizes with Cit1810-RNAP2 and with S2P-RNAP2 (**Figure S2I**). These observations support the association of PADI2 with Cit1810-RNAP2 that is engaged in transcription.

## Citrullination of R1810 regulates transcription and cell proliferation

We next performed mRNA sequencing in control and PADI2 depleted T47D cells (**Figure S3A**). Strikingly, in global differential expression (DEseq) analysis PADI2 knockdown affected the expression of over 4,000 genes; down regulated (2,186) and up regulated (2,141) (**Figure 3A, Figure S3B**). Gene ontology analysis of the down-regulated genes revealed enrichment in RNAP2-mediated transcription and cell proliferation (**Figure S3C and Table S1**). Reduced expression was validated by RT-qPCR for several genes including *SERPINA6*, *c-MYC*, and *HMGNI* genes, while control genes *GSTT2* and *LRRC39* were not affected (**Figure 3B, Figure S3D**). Depletion of CARM1 or PRMT5, which catalyze dimethylation of R1810 (Sim et al., 2011; Zhao et al., 2016), did not affect the expression of PADI2-dependent genes (**Figure S3E-F**).

To explore the direct effect of PADI2 on nascent transcription, we performed chromatin-associated RNA sequencing (ChrRNA-seq, Nojima et al., 2016) in control and PADI2 depleted cells. We found that ~2,000 transcripts were significantly affected by the PADI2 knockdown, and the majority of them were down regulated (1,884, **Figure 3C-D, Figure S3G**). ChrRNA-seq changes were validated on PADI2-dependent genes by RT-qPCR (**Figure 3E**). We conclude that PADI2 is required for efficient transcription and that up regulation of mRNAs upon PADI2 depletion may be a consequence of down-regulation of transcription relevant genes, although we cannot exclude citrullination of other PADI2 substrates. To support this conclusion, we performed mRNA sequencing in T47D cells expressing only the  $\alpha$ -amanitin resistant HA-tagged WT<sup>r</sup> or the R1810A<sup>r</sup> mutant form of RNAP2. We found 1,392 down-regulated genes in cells expressing R1810A<sup>r</sup> mutant RNAP2, of which 939 (67.4%) were also dependent on PADI2. We confirmed this finding by RT-qPCR of a PADI2-dependent *SERPINA6*, *c-MYC*, and *HMGNI* and control genes *GSTT2* and *LRRC39* (**Figure 3F**). Thus, PADI2 and R1810 are required for efficient transcription.

Since many PADI2 and R1810-dependent genes are related to cell proliferation, we monitored T47D cell proliferation after PADI2 depletion (si*PADI2*), inhibition with Cl-amidine, or in cells expressing only the R1810A<sup>r</sup> mutant of RNAP2. In all cases, we found a significant reduction of cell proliferation (**Figure 3G**). PADI2-depleted cells were arrested at the G1 phase of the cell cycle (**Figure S3H**), as expected given the down regulation of genes critical for G1 phase progression including *CCND1*, *PLK1* in presence of R1810A<sup>r</sup> mutant as compared to WT<sup>r</sup> RNAP2 or PADI2 depletion (**Figure 3H, Table S2, Figure S3I-K**).

### **PADI2 is enriched on active genes**

ChIP-seq of PADI2 in T47D cells showed that 60% of chromatin-bound PADI2 was localized over protein-coding gene sequences, within 3kb upstream of the TSS (transcription start site) and 3kb downstream of the TTS (transcription termination site) (q value  $\leq 0.005$ ) (**Figure 4A, left panel**). The highest enrichment (2.5-fold) was found in the coding exons, followed by the 3kb region downstream of the TTS (1.6-fold) (**Figure 4A, Right panel**). Overall, PADI2 occupancy overlapped with RNAP2 binding measured by ChIP-seq (**Figure 4B**). To explore whether PADI2 binding is related to transcription, we separated genes in 4 quartiles according to their transcription level: high (100-95%), medium (95%-50%), low (last 50%) and silent (non-significant expression) (Baranello et al., 2016). We found that RNAP2 and PADI2 occupancy increased in parallel with the gene expression levels (**Figure 4C, Figure S4A**), supporting a role of PADI2 in transcription.

To verify the specificity of the PADI2 occupancy, we performed PADI2 ChIP-qPCR in control (si*CTRL*) and PADI2 knockdown (si*PADI2*) over high (*SERPINA6*, *c-MYC*) and low expressed (*GSTT2*) genes and found that PADI2 depletion drastically decreased the levels (**Figure S4B**). PADI2 occupancy was significantly higher on genes down regulated by PADI2 depletion compared to those non-regulated (**Figure S4C**). Finally, RNAP2-ChIP followed by PADI2 re-ChIP revealed the association of RNAP2 and PADI2 at regulatory regions and gene bodies of the highly transcribed *SERPINA6*, *c-MYC* genes, but not in the low expressed *GSTT2* gene (**Figure S4D**). Thus, PADI2 seemed to be part of the transcription machinery in highly expressed genes.



### **Citrullination of R1810 controls RNAP2 pausing**

Next, we analyzed RNAP2 occupancy by ChIP-qPCR in T47D cells prior and after PADI2 depletion. We observed accumulation of RNAP2 around the TSS of the highly expressed *SERPINA6*, *c-MYC*, *HMGNI* genes (**Figure S5A**, **Figure S5B right panel**). This effect is also dependent on R1810, as it is observed in T47D cells expressing only the  $\alpha$ -amanitin resistant HA-tagged R1810A<sup>r</sup> mutant form of RNAP2 in comparison with cells expressing only the WT<sup>r</sup> RNAP2 (**Figure 5A**, **Figure S5B left panel**), suggesting absence of PADI2 mediated citrullination of R1810 leads to RNAP2 pausing. In T47D cells expressing only the R1810A mutant compared to cells expressing the WT<sup>r</sup> RNAP2, ChIP-seq experiments showed remarkably high accumulation of RNAP2 at proximal promoters (**Figure 5B**) and a corresponding change in the pausing index that correlated with the gene expression levels (**Figure 5C**). Previously, Raji cells expressing R1810A also showed paused RNAP2 at proximal promoter for the 5% most highly expressed genes (Zhao et al., 2016).

Focusing on PADI2-dependent genes (n=2186), we found a pronounced accumulation of RNAP2 around the TSS with a significantly increased pausing index in presence of R1810A mutant as compared to wild-type form of RNAP2 (**Figure 5D-F**). Similarly, genes down regulated in the presence of the R1810A<sup>r</sup> RNAP2 mutant (n=939) also showed significantly higher pausing index as compared to cells expressing WT<sup>r</sup> RNAP2 (**Figure S5D**). Thus, PADI2 depletion or absence of R1810 lead to RNAP2 accumulation on the promoters of highly expressed genes and to reduced level of S2P and S5P forms of RNAP2 (**Figure S5C**). We also found that genes up regulated upon depleting PADI2 or upon expressing the R1810A<sup>r</sup> mutant RNAP2 exhibited lower pausing index (**Figure S5E-F**), suggesting that they do not need to overcome RNAP2 pausing to maintain their expression. In summary, we found that PADI2 citrullination of CTD R1810 is important for RNAP2 promoter pause release.

### **Cit1810 at RNAP2-CTD recognized by P-TEFb**

Citrullination is known to modulate functional protein-protein interactions (Tanikawa et al., 2018; Tanikawa et al., 2012; Vossenaar et al., 2003). We wondered whether the Cit1810 influences the interaction of RNAP2 with the components of P-TEFb complex CDK9 and CCNT1 (Cyclin T1), which are required for RNAP2 pause release and productive elongation (Jonkers et al. 2015; Gressel et al., 2017). Immunoprecipitation of T47D cells extracts with a PADI2 antibody, precipitated CDK9 and CCNT1 (**Figure 6A, left panel**) and conversely a CDK9 antibody pulled down PADI2 (**Figure 6A, right panel**), indicating that PADI2 associates with the P-TEFb complex. Immunoprecipitation of extracts from PADI2 depleted cells (*siPADI2*) showed strong reduction in RNAP2 interaction with CDK9 and CCNT1 compared to control cells (*siCTRL*) (**Figure 6B**). In T47D or Raji cells expressing only the  $\alpha$ -amanitin resistant HA-tagged WT<sup>r</sup> RNAP2, CDK9 and CCNT1 were also immunoprecipitated with HA-tag antibody, and the interaction was significantly reduced in cells expressing the R1810A<sup>r</sup> mutant RNAP2 (**Figure 6C-D**). Thus, PADI2 and R1810 are required for the association of RNAP2 with the CDK9-CCNT1 complex. Next, we performed peptide pull-down assays with T47D nuclear extracts using biotinylated wild type (R1810) and cit1810 RNAP2-CTD peptides (**Figure 6E, upper panel**). The cit1810 peptide pulls down the CDK9-CCNT1 complex much more efficiently than the wild type peptide (R1810) (**Figure 6E, lower panel**), confirming that PADI2 mediated cit1810 is required to facilitate cooperation of RNAP2 with CDK9-CCNT1 complex.

To explore whether R1810 is important for CDK9 recruitment to the promoter region of genes, we performed ChIP-seq with CDK9-antibody in T47D cells expressing only the  $\alpha$ -amanitin resistant HA-tagged R1810A<sup>r</sup> or the WT<sup>r</sup> RNAP2. We found that CDK9 occupancy around the TSS decreased remarkably in the presence of R1810A mutant compared to wild-type form of RNAP2, particularly in highly expressed genes (**Figure 6F**), suggesting that the integrity of the R1810 is required for CDK9 recruitment. When we compared PADI2 dependent and non-dependent genes we also found a significant decrease of CDK9 occupancy in the presence of R1810A mutant as compared to wild-type form of RNAP2 (**Figure 6G**). We validated the ChIP-seq results by ChIP-qPCR and confirmed that mutation of R1810 significantly decrease the recruitment of the CDK9 to the promoter of PADI2 target genes *SERPINA6*, *c-MYC*, *HMGNI*, but not to the low expressed genes *GSST2* and *LRRC39* (**Figure 6H**). Altogether, these data support the idea that PADI2 mediated citrullination of R1810 at

RNAP2-CTD facilitates the recruitment of P-TEFb complex that promotes RNAP2 pause release and transcription of actively expressed genes involved in cellular proliferation.

### **PADI2 unique residues contribute to citrullinate R1810 at RNAP2-CTD**

We wondered about the reason why only PADI2 but not PADI3 or nor PADI4 carries out citrullination of R1810 at RNAP2-CTD. To address this issue, we used the published structure of the PADI2 (Slade et al., 2015) to model the attachment of RNAP2-CTD peptide encompassing R1810 (**Figure 7A**), and performed a similar structural modeling with the amino acids of PADI3. Our analysis revealed that the predicted binding score energies calculated with Rosetta were significantly lower for PADI2 in comparison to PADI3 (**Figure 7B**, **movie S1-S2**, see method), indicating a higher affinity of PADI2 for the R1810 peptide.

We next examined the PADI2 residues contributing most to the affinity for the R1810 peptide and analyzed their conservation in the PADI family. We found that non-conserved residues in PADI2 accumulate at the rim of the catalytic domain (**Figure S6**), most likely contributing to the R1810 peptide binding. We calculated Rosetta score for all PADI2 interface residues (including conserved and non-conserved) and ranked them according to conservation among PADI family members (**Figure S7A and Table S3**). Next, we choose PADI2 specific residues R580 and L642 and also two other PADI conserved residues D374 and S401 that showed comparable low binding energy of PADI2 toward the R1810 peptide (**Figure 7A, Figure S7A**), and introduced mutations that changed chemical properties of these four residues while maintaining the volume (**Figure S7B**). Using GST C-CTD that encompasses R1810 as a substrate for *in vitro* citrullination assays, we found that the R580E and L642T mutations drastically reduced citrullination activity, whereas the D374K and S401A have a non-significant effect (**Figure 7C**), confirming the specificity of PADI2 unique residues for citrullination of R1810.

## DISCUSSION

In this study, we identify a novel post-translational modification of the RNAP2-CTD, namely the citrullination by PADI2 of R1810. This modification is coupled with the active form of RNAP2 and regulates the transcription of highly expressed genes involved in cell proliferation by mediating the interaction with P-TEFb complex and favoring RNAP2 pause release. We detected this modification initially in T47D breast cancer cells with a pan-citrulline antibody and confirmed it with Cit1810 antibody generated using a 13-mer CTD peptide centered on Cit1810. In breast cancer cells, PADI2 but not PADI3 or PADI4 specifically catalyze R1810 citrullination. Inhibition or depletion of PADI2 compromises transcription of thousands of highly expressed genes, as monitored by mRNA-seq analysis. Many of these PADI2-dependent genes are involved in key biological functions including RNAP2 transcription and cell proliferation. In chromatin RNA-seq, we found that PADI2 is mainly involved in active transcription, leading us to conclude that PADI2 participates in facilitating active transcription. However, in mRNA-seq analysis we also find genes up-regulated upon PADI2 depletion. Their up-regulation could be an indirect consequence of changes in the expression of PADI2-dependent genes or could be related to the need of R1810 dimethylation for proper transcription termination (Zhang et al., 2016). This remains to be directly demonstrated.

The previously reported asymmetrical (Sims et al., 2011) and symmetrical (Zhang et al., 2016) dimethylation of R1810 occurs mainly in hypo-phosphorylated RNAP2, as detected only after phosphatase treatment. In contrast, we find that cit1810 is preferentially associated with the transcriptionally engaged phosphorylated RNAP2. Depletion of the methyltransferases responsible for R1810 dimethylation, CARM1 and PRMT5, did not affect the expression of PADI2 dependent genes, and depletion of PADI2 did not change the expression of a broad range of snRNAs, the targets of CARM1. As PADI2 can not act on methylated R1810, and citrullination will preclude methylation by arginine methyltransferases, it seems that these are alternative types of modifications influencing different stages of transcription, as observed in other arginine residues that can undergo methylation and citrullination (Tanikawa et al. 2018; Cuthbert et al., 2004). This implies the dynamic nature of R1810 modifications, that change the

docking surface for regulatory protein complexes to control various phases of transcription.

Our results of RNAP2 ChIP-seq show that PADI2 mediated cit1810 is required for RNAP2 pause release or high turnover (Krebs et al., 2017) at promoters of highly expressed genes that maintain cellular proliferation (Day et al., 2016; Gilchrist et al., 2010; Zeitlinger et al., 2007). In search for the molecular mechanism, we found that PADI2 interacts with the P-TEFb kinase complex, which is needed for RNAP2 pause release and productive transcript elongation. This interaction depends on R1810, supporting a function of cit1810 to facilitate transcription. Most likely, citrullination of R1810 at RNAP2-CTD is the key mechanism to maintain the transcription level of highly expressed genes involved in tumor progression and metastasis, essentially needed to overcome the RNAP2 pausing. This assumption is coherent with the recent findings that inhibition of PAD2 activity suppress the mammary gland tumor invasion in mice (Horibata, S., et al., 2017) and reduces the mammary cancer progression in dogs and cats (Ledet., M.M et al., 2018). Remarkably, PADI2 null mice are viable (Van Beers et al. 2013), suggesting that PADI2 mediated cit1810 RNAP2-CTD is not needed during normal development or that this function is fulfilled by another member of the PADI family. This last possibility seems unlikely, as by modeling the structure of PADI2 with the bound R1810 CTD peptide, we identified essential PADI2-specific amino acid residues that are not conserved in other PADI family members.

Although our results support a function of PADI2 mediated citrullination of CTD R1810 in transcription elongation, we cannot exclude an pleiotropic action of PADI2 on other substrates, including citrullination arginine 26 at histone H3 (H3R26), which could be involved in local chromatin decondensation and transcription activation (Zhang et al. 2012). Another intriguing open question concerns the implications of the proposed irreversibility of the citrullination reaction (Cuthbert et al., 2004; Wang et al., 2004). In the absence of enzymes that erase citrullination, alternative mechanisms may exit to replace the citrullinated RNAP2 before reaching transcription termination. Given that arginine-mediated interactions between intrinsically disordered protein domains, including the CTD of RNAP2, and RNAs or Poly(ADP-Ribose) are important in the formation of liquid droplets within the cell nucleus (Altmeyer et al. 2015; Hnisz et al. 2017; Harlen et al., 2017), we cannot exclude that citrullination of R1810 could also

participate in modulating this interactions, and those influencing transcriptional output. Further work will be required to investigate these possibilities.

Many elongation factors and kinases are implicated in the control of RNAP2 transcription pause release, a mechanism that controls the expression of genes involved in cancer progression and metastasis, like CDK9, MYC, JMJD6 (Zhang et al., 2017; Bywater et al., 2013; Miller et al., 2017). PADI2 is also found overexpressed in breast cancer (Cherrington et al., 2012) and other cancers (Guo et al., 2017). Indeed, we found that PADI2 depletion or mutation of R1810 reduced cell proliferation of breast cancer cells, by modulating cell cycle progression. Also, among *PADI* family members, only *PADI2* is overexpressed in breast cancer and other cancers and its overexpression correlates with poor prognosis (Cherrington et al. 2012; Curtis et al., 2012; Richardson et al., 2006; Cancer Genome Atlas Network. et al., 2012; Adib et al., 2004; Brune et al., 2008; Cho et al., 2011; Compagno et al., 2009; Hou et al., 2010; Murat et al., 2008; Gyorffy et al., 2010; Gyorffy et al., 2013; Szász et al., 2016; Vathipadiekal et al., 2015). Thus, our finding opens the possibility that specific inhibition of citrullination at R1810-RNAP2 may represent a suitable drug target.

## ACKNOWLEDGEMENTS

We thank David Bentley, for GST-CTD plasmids; Hiroshi Kimura, for RNAP2 S2P/5P monoclonal antibodies. We thank CRG Genomics, Protein Technology and the Advanced Light Microscopy facilities for all technical support. We are grateful to all the members of the chromatin and gene expression lab for useful suggestions. We acknowledge Juan Valcárcel, Guillermo P. Vicent, Enrique Vidal Ocabo, and Gwendal Dujardin from CRG for constructive criticism and advice during the course of this work. P.S. was supported by a Novartis fellowship and Beatriu de Pinós fellowship (co-funded by Marie Curie Action, 2013 BP\_B 00061). Our work supported by Spanish MEC (SAF2013-42497), the Catalan Government (AGAUR 2014SGR780) and the European Research Council Synergy Grant “4DGenome” (609989). We acknowledge the support of the Spanish Ministry of Economy and Competitiveness, ‘Centro de Excelencia Severo Ochoa’ and the CERCA Programme / Generalitat de Catalunya”.

## AUTHOR CONTRIBUTIONS

Conceptualization, P.S. and M.B.; Methodology, P.S. and M.B.; Investigation, P.S., A.L., C.D.V., F.L.D.; Formal Analysis, P.S., J.Q., J.C.C., N.F.F., and A.L.; Data Curation, P.S., J.Q., J.C.C., N.F.F., R.H.G.W., and B.O.; Visualization, P.S. and M.B., Project Administration, P.S., Writing-Original Draft, P.S. and M.B.; Writing-Review & Editing, P.S., M.B., D.E. A.L., N.F.F., F.L.D. J.Q., and R.H.G.W.; Funding Acquisition, M.B. and P.S.; Resources, R.S and D.E.; Supervision, P.S., M.B.

## DECLARATION OF INTERESTS

The authors declare no competing financial interests.

## REFERENCES

- Adelman, K., Lis, J.T. (2012). Promoter-proximal pausing of RNA polymerase II: emerging roles in metazoans. *Nat. Rev. Genet.* *13*, 720-31.
- Adib, T.R., Henderson, S., Perrett, C., Hewitt, D., Bourmpoulia, D., Ledermann, J., Boshoff, C. (2004). Predicting biomarkers for ovarian cancer using gene-expression microarrays. *Br J Cancer* *90*, 686-692.
- Altmeyer, M., Neelsen, K.J., Teloni, F., Pozdnyakova, I., Pellegrino, S., Grøfte, M., Rask, M.B., Streicher, W., Jungmichel, S., Nielsen, M.L., et al. (2015). Liquid demixing of intrinsically disordered proteins is seeded by poly(ADP-ribose). *Nat Commun.* *6*:8088.
- Arita, K., Shimizu, T., Hashimoto, H., Hidaka, Y., Yamada, M., Sato, M. (2006). Structural basis for histone N-terminal recognition by human peptidylarginine deiminase 4. *Proc. Natl. Acad. Sci. U.S.A.* *103*, 5291-5296.
- Baka Z.I., György B., Géher P., Buzás E.I., Falus A., Nagy G. (2012). Citrullination under physiological and pathological conditions. *Joint Bone Spine.* *79*, 431-6.
- Baker, D., Sali, A. (2001). Protein structure prediction and structural genomics. *Science* *294*, 93-96.
- Baranello, L., Wojtowicz, D., Cui, K., Devaiah, B.N., Chung, H.J., Chan-Salis K.Y., Guha. R., Wilson, K., Zhang, X., Zhang. H., et al. (2016). RNA Polymerase II Regulates Topoisomerase 1 activity to favor efficient transcription. *Cell* *165*, 357-371.

Bentley D. (1999). Coupling RNA polymerase II transcription with pre mRNA processing. *Curr. Opin. Cell Biol.* 3, 347-51.

Berman, H.M., Westbrook, J., Feng, Z., Gilland, G., Bhat, T.N., Weissig, H., Shindyalov, I.N., Bourne, P.E. (2000). The Protein Data Bank. *Nucleic Acids Res*, 28, 235-242.

Bolger, A.M., Lohse, M., Usadel, B. (2014) Trimmomatic: a flexible trimmer for Illumina sequence data. *Bioinformatics* 30:2114–2120.

Bray, N.L., Pimentel, H., Melsted, P., Pachter, L. (2016). Near-optimal probabilistic RNA-seq quantification. *Nature Biotechnology* 34, 525–527.

Brune, V., Tiacchi, E., Pfeil, I., Döring, C., Eckerle, S., van Noesel, C.J., Klapper, W., Falini, B., von Heydebreck, A., Metzler, D., et al. (2008). Origin and pathogenesis of nodular lymphocyte-predominant Hodgkin lymphoma as revealed by global gene expression analysis. *J Exp Med* 205, 2251-2268.

Buratowski, S. (2009). Progression through the RNA polymerase II CTD cycle. *Mol. Cell* 36, 541-546.

Bywater, M.J., Pearson, R.B., McArthur, G.A., Hannan, R.D. (2013). Dysregulation of the basal RNA polymerase transcription apparatus in cancer. *Nat Rev Cancer* 13, 299-314.

Cancer Genome Atlas Network., et al. (2012). Comprehensive molecular portraits of human breast tumours. *Nature* 490, 61-70.

Chen, F.X., Woodfin, A.R., Gardini, A., Rickels, R.A., Marshall, S.A., Smith, E.R., Shiekhata, R., Shilatifard, A. (2015). PAFI, a molecular regulator of promoter proximal pausing by RNA Polymerase II. *Cell* 162,1003-15.

Cherrington, B.D., Zhang, X., McElwee, J.L., Morency, E., Anguish, L.J., Coonrod, S.A. (2012). Potential role of PAD2 in gene regulation in breast cancer cells. *PLoS One*. 7, e41242.

Cho, J.Y., Lim, J.Y., Cheong, J.H., Park, Y.Y., Yoon, S.L., Kim, S.M., Kim, S.B., Kim, H., Hong, S.W., Park, Y.N., et al. (2011). Gene expression signature-based prognostic risk score in gastric cancer. *Clin Cancer Res* 17, 1850-1857.

Christophorou, M.A., Castelo-Branco, G., Halley-Stoott, R.P., Oliveira, C.S., Loos, R., Radziskeuskaya, A., Mowen, K.A., Bertone, P., Silva, J.C., Zernicka-Goetz, M., et al. (2014). Citrullination regulates pluripotency and histone H1 binding to chromatin. *Nature* 507, 104-108.

Compagno, M., Lim, W.K., Grunn, A., Nandula, S.V., Brahmachary, M., Shen, Q., Bertoni, F., Ponzoni, M., Scandurra, M., Califano, A. et al. (2009). Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. *Nature* 459, 717-721.



Corden, J.L. (2013). RNA polymerase II C-terminal domain: Tethering transcription to transcript and template. *Chem. Rev.* *113*, 8423-8455.

Corden, J.L. (2016). PolII CTD code light. *Mol. Cell* *61*, 183-4.

Core, L.J., Waterfall, J.J., Lis, J.T. (2008). Nascent RNA sequencing reveals widespread pausing and divergent initiation at human promoters. *Science* *322*, 1845-8.

Curtis, C., Shah, S.P., Chin, S.F., Turashvili, G., Rueda, O.M., Dunning, M.J., Speed, D., Lynch, A.G., Samarajiwa, S., Yuan, Y. et al. (2012). The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. *Nature* *486*, 346-352.

Cuthbert, G.L., Daujat, S., Snowden, A.W., Erdjument Bromage H., Hagiwara, T., Yamada, M., Schneider, R., Gregory, P.D., Tempst, P., Bannister, A.J., et al. (2004). Histone deimination antagonizes arginine methylation. *Cell* *118*, 545-553.

Day, D.S., Zhang, B., Stevens, S.M., Ferrari, F., Larschan, E.N., Park, P.J., Pu, W.T. (2016). Comprehensive analysis of promoter proximal RNA polymerase II pausing across mammalian cell types. *Genome Biol.* *17*, 120.

Dias, J.D., Rito, T., Torlai Triglia E., Kukalev, A., Ferrai, C., Chotalia, M., Brookes, E., Kimura, H., Pombo, A. (2015). Methylation of RNA polymerase II non-consensus Lysine residues marks early transcription in mammalian cells. *elife* *4*, e11215.

Eick, D., Geyer, M. (2013). The RNA polymerase II carboxy-terminal domain (CTD) code. *Chem. Rev.* *113*, 8456–8490.

Fay, A.L., Tyka, M., Lewis, S.M., Lange, O.F., Thompson, J., Jacak, R., Kaufman, K., Renfrew, P.D., Smith, C.A., Sheffler, W., et al. (2011). ROSETTA3: an object-oriented software suite for the simulation and design of macromolecules. *Methods Enzymol.* *487*, 545-574.

Fuentes, N.F., Madrid-Aliste, C.J., Rai, B.K., Fajardo, J.E., Fiser, A. (2007). M4T: a comparative protein structure modeling server. *Nucleic Acids Research* *35*, W363-368.

Fuhrmann, J., Clancy, K.W. (2015). Thompson, P.R. Chemical biology of protein arginine modifications in epigenetic regulation. *Chem. Rev.* *115*, 5413-61.

Gilchrist, D.A., Dos Santos G., Fargo, D.C., Xie B., Gao Y., Li, L., Adelman K. (2010). Pausing of RNA polymerase II disrupts DNA-specified nucleosome organization to enable precise gene regulation. *Cell* *143*, 540-51.

Gressel, S., Schwalb, B., Decker, T.M., Qin, W., Leonhardt, H., Eick, D., Cramer, P. (2017). CDK9-dependent RNA polymerase II pausing controls transcription initiation. *eLife* *6*, e29736.

Guo, W., Zheng, Y., Xu, B., Ma, F., Li, C., Zhang, X., Wang, Y., Chang, X. (2017). Investigating the expression, effect and tumorigenic pathway of PADI2 in tumors. *Oncotargets Ther* *10*, 1475-1485.

Gyorgy, B., Toth, E., Tarcsa, E., Falus, A., Buzas, E.I. (2006). Citrullination: a posttranslational modification in health and disease. *Int J Biochem Cell Biol* 38, 1662-1677

Gyorffy, B., Lanczky, A., Eklund, A.C., Denkert, C., Budczies, J., Li, Q., Szallasi, Z. (2010). An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. *Breast Cancer Res. Treat.* 123, 725-731.

Gyorffy, B., Lanczky, A., Szallasi, Z. (2012). Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients. *Endocr Relat Cancer* 19, 197-208.

Gyorffy, B., Surowiak, P., Budczies, J., Lanczky, A. (2013). Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer. *PLoS One* 8, e82241.

Harlen, K.M., Churchman, L.S. (2017). The code and beyond: transcription regulation by the RNA polymerase II carboxy-terminal domain. *Nat. Rev. Mol. Cell. Biol.* 18, 263-273.

Heinz, S., Benner, C., Spann, N., Bertolino, E., Lin, Y.C., Laslo, P., Cheng, J.X., Murre, C., Singh, H., Glass, C.K. (2010). Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. *Mol. Cell* 38, 576-589.

Hnisz, D., Shrinivas, K., Young, R.A., Chakraborty, A.K., Sharp, P.A. (2017). A Phase Separation Model for Transcriptional Control. *Cell* 169:13-23.

Horibata, S., Rogers, K.E., Sadegh, D., Anguish, L.J., McElwee, J.L., Shah, P., Thompson, P.R., Coonrod, S.A. (2017). Role of peptidylarginine deiminase 2 (PAD2) in mammary carcinoma cell migration. *BMC Cancer* 17, 378.

Hou, J., Aerts, J., den Hamer, B., van Ijcken, W., den Bakker, M., Riegman, P., van der Leest, C., van der Spek, P., Foekens, J.A., Hoogsteden, H.C., et al. (2010). Gene expression-based classification of non-small cell lung carcinomas and survival prediction. *PLoS One* 5, e10312.

Iannone, C., Pohl, A., Papasaikas, P., Soronellas, D., Vicent, G.P., Beato, M., Valcárcel, J. (2015). Relationship between nucleosome positioning and progesterone-induced alternative splicing in breast cancer cells. *RNA* 21, 360-374.

Jerabek-Willemsen, M., Wienken, C.J., Braun, D., Baaske, P., Duhr, S. (2011). Molecular interaction studies using microscale thermophoresis. *Assay Drug Dev Technol* 9, 342-353.

Jeronimo, C., Collin, P., Robert, F. (2016). The RNA Polymerase II CTD: The Increasing Complexity of a Low-Complexity Protein Domain. *J. Mol. Biol.* 428, 2607-2622.

- Jonkers, I., Lis, J.T. (2015). Getting up to speed with transcription elongation by RNA polymerase II. *Nat Rev Mol. Cell Biol.* *16*, 167-177.
- King, C.A., Bradley, P. (2010). Structure-based prediction of protein-peptide specificity in Rosetta. *Proteins* *78*, 3437-3449.
- Krebs, A.R., Imanci, D., Hoerner, L., Gaidatzis, D., Burger, L., Schübeler, D. (2017). Genome-wide single molecule footprinting reveals high RNA polymerase II turnover at paused promoters. *Mol. Cell* *67*, 411-422.
- Langmead, B., Trapnell, C., Pop, M., Salzberg, S.L. (2009). Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. *Genome Biology* *10*, r25.
- Laskowski, R.A., MacArthur, M.W., Moss, D.S., Thornton, J.M. (1993). PROCHECK: a program to check the stereochemical quality of protein structures. *J Appl. Cryst.* *26*, 283-291.
- Ledet, M.M., Anderson, R., Harman, R., Muth, A., Thompson, P.R., Coonrod, S.A., Van de Walle G.R., (2018). BB-CI-Amidine as a novel therapeutic for canine and feline mammary cancer via activation of the endoplasmic reticulum stress pathway. *BMC Cancer.* *18*, 412.
- Livingstone, C.D., Barton, G.J. (1993). Protein sequence alignments: a strategy for the hierarchical analysis of residue conservation. *Comput. Appl. Biosci.* *9*, 745-756.
- Love, M.I., Huber, W., Anders, S. (2014). Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol.* *15*, 550.
- Marshall, N.F., Price, D.H. (1995). Purification of P-TEFb, a transcription factor required for the transition into productive elongation. *J. Biol. Chem.* *270*, 12335-8.
- Meininghaus, M., Chapman, R.D., Horndasch, M., Eick, D. (2000). Conditional expression of RNA polymerase II in mammalian cells. Deletion of the carboxyl-terminal domain of the large subunit affects early steps in transcription. *J. Biol. Chem.* *275*, 24375-24382.
- Murat, A., Migliavacca, E., Gorlia, T., Lambiv, W.L., Shay, T., Hamou, M.F., de Tribolet, N., Regli, L., Wick, W., Kouwenhoven, M.C., et al. (2008). Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. *J Clin Oncol* *26*, 3015-3024.
- Miller, T.E. Liao, B.B., Wallace, L.C., Morton, A.R., Xie, Q., Dixit, D., Factor, D.C., Kim, L.J.Y., Morrow, J.J., Wu, Q., et al., (2017). Transcription elongation factors represent *in vivo* cancer dependencies in glioblastoma. *Nature* *547*, 355-359.
- Mohanan, S., Cherrington, B.D., Horibata, S., McElwee, J.L., Thompson, P.R., Coonrod, S.A. (2012). Potential role of peptidylarginine deiminase enzymes and protein citrullination in cancer pathogenesis. *Biochem. Res. Int.* *2012*, 895343.

Nojima, T., Gomes, T., Carmo-Fonseca, M., Proudfoot, N.J. (2016). Mammalian NET-seq analysis defines nascent RNA profiles and associated RNA processing genome-wide. *Nat Protoc* 11, 413-428.

Pau, G., Fuchs, F., Sklyar, O., Boutros, M., Huber, W. (2010). EBImage--an R package for image processing with applications to cellular phenotypes. *Bioinformatics* 26, 979-981.

Pohl, A., Beato, M. (2014). bwtool: a tool for bigWig files. *Bioinformatics* 30, 1618-1619.

Ramírez, F., Ryan, D.P., Grüning, B., Bhardwaj, V., Kilpert, F., Richter, A.S., Heyne, S., Dündar, F., Manke, T. (2016). deepTools2: a next generation web server for deep-sequencing data analysis. *Nucleic Acids Res.* 44, 160-5.

R core team (2017). R: A language and environment for statistical computing.

Richardson, A.L., Wang, Z.C., De Nicolo, A., Lu, X., Brown, M., Miron, A., Liao, X., Iglehart, J.D., Livingston, D.M., Ganesan, S. (2006). X chromosomal abnormalities in basal-like human breast cancer. *Cancer Cell* 9, 121-132.

Saldi, T., Cortazar, M.A., Sheridan, R.M., Bentley, D.L. (2016). Coupling of RNA Polymerase II Transcription Elongation with Pre-mRNA Splicing. *J. Mol. Biol.* 428, 2623-2635.

Schindelin, J., Arganda-Carreras, I., Frise, E., Kaynig, V., Longair, M., Pietzsch, T., Preibisch, S., Rueden, C., Saalfeld, S., Schmid, B. et al. (2012). Fiji: an open-source platform for biological-image analysis. *Nat. Methods* 9, 676-82.

Schüller, R., Forné, I., Straub, T., Schrieck, A., Texier, Y., Shah, N., Decker, T.M., Cramer, P., Imhof, A., Eick, D. (2016). Heptad-Specific Phosphorylation of RNA Polymerase II CTD. *Mol. Cell* 61, 305-14.

Shah, N., Maqbool, M.A., Yahia, Y., El Aabidine, A.Z., Esnault, C., Forné, I., Decker, T.M., Martin, D., Schüller, R., Krebs, S., et al. (2018). Tyrosine-1 of RNA polymerase II CTD controls global termination of gene transcription in mammals. *Mol. Cell* 69, 48-61.

Shao, W., Zeitlinger, J. (2017). Paused RNA polymerase II inhibits new transcriptional initiation. *Nat. Genet.* 49, 1045-51.

Sharma, P., Azebi, S., England, P., Christensen, T., Møller-Larsen, A., Petersen, T., Batsché, E., Muchardt, C. (2012). Citrullination of histone H3 interferes with HP1-mediated transcriptional repression. *PLoS Genet.* 8, e1002934.

Sims, R.J., Rojas, L.A., Beck, D.B., Bonasio, R., Schüller, R., Drury, W.J., Eick, D., Reinberg, D. (2011). The C-terminal domain of RNA polymerase II is modified by site-specific methylation. *Science* 332, 99-103.

Sippl, M.J. (1993). Recognition of errors in three-dimensional structures of proteins. *Proteins* 17, 355.

Slade, D.J. Fang, P., Dreyton, C.J., Zhang, Y., Fuhrmann, J., Rempel, D., Bax, B.D., Coonrod, S.A., Lewis, H.D., Guo, M., et al. (2015). Protein Arginine Deiminase 2 Binds Calcium in an Ordered Fashion: Implications for Inhibitor Design. *ACS Chem. Biol.* 10, 1043–1053.

Slade, D.J., Subramanian, V., Fuhrmann, J., Thompson, P.R. (2014). Chemical and biological methods to detect post-translational modifications of arginine. *Biopolymer* 101, 133-43.

Subramanian, A., Tamayo, P., Mootha, V.K., Mukherjee, S., Ebert, B.L., Gillette, M.A., Paulovich, A., Pomeroy, S.L., Golub, T.R., Lander, E.S., et al. (2005). Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc. Natl. Acad. Sci. U.S.A.* 102, 15545-15550.

Szász A.M., Lánckzy, A., Nagy, Á., Förster, S., Hark, K., Green, J.E., Boussioutas, A., Busuttill, R., Szabó, A., Györffy, B. (2016). Cross-validation of survival associated biomarkers in gastric cancer using transcriptomic data of 1,065 patients. *Oncotarget* 7, 49322-49333.

Tanikawa, C., Espinosa, M., Suzuki, A., Masuda, K., Yamamoto, K., Tsuchiya, E., Ueda, K., Daigo, Y., Nakamura, Y., Matsuda, K. (2012). Regulation of histone modification and chromatin structure by the p53-PADI4 pathway. *Nat. Commun.* 3, 676.

Tanikawa, C., Ueda, K., Suzuki, A., Iida, A., Nakamura, R., Atsuta, N., Tohnai, G., Sobue, G., Saichi, N., Momozawa, Y., et al. (2018). Citrullination of RGG motifs in FET Proteins by PAD4 regulates protein aggregation and ALS susceptibility. *Cell Rep.* 22,1473-1483.

Thompson, J.D., Higgins, D.G., Gibson, T.J. (1994). CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. *Nucleic Acids Res.* 22, 4673.

Truss, M., Bartsch, J., Schelbert, A., Haché R.J., Beato, M. (1995). Hormone induces binding of receptors and transcription factors to a rearranged nucleosome on the MMTV promoter in vivo. *The EMBO Journal* 14, 1737-1751.

Van Beers, J.J., Zendman, A.J., Raijmakers, R., Stammen, V. J., Pruijn, G.J., (2013). Peptidylarginine deiminase expression and activity in PAD2 knock-out and PAD4-low mice. *Biochimie.* 95:299-308.

Van Venrooij W.J., Pruijn G.J. (2000). Citrullination: a small change for a protein with great consequences for rheumatoid arthritis. *Arthritis Res.* 2, 249-51.

Vathipadiekal, V., Wang, V., Wei, W., Waldron, L., Drapkin, R., Gillette, M., Skates, S., Birrer, M. (2015). Creation of a Human Secretome: A Novel Composite Library of

Human Secreted Proteins: Validation Using Ovarian Cancer Gene Expression Data and a Virtual Secretome Array. *Clin Cancer Res* 21, 4960-4969.

Vicent, G.P., Zaurin, R., Nacht, A.S., Li, A., Font-Mateu, J., Le Dily, F., Vermeulen, M., Mann, M., Beato, M. (2009). Two chromatin remodeling activities cooperate during activation of hormone responsive promoters. *PLoS Genet* 5, e1000567.

Vicent, G.P., Nacht, A.S., Ballaré, C., Zaurin, R., Soronellas, D., Beato, M. (2014). Progesterone receptor interaction with chromatin. *Methods Mol. Biol.* 1204, 1-14

Voss, K., Forné, I., Descostes, N., Hintermair, C., Schüller, R., Maqbool, M.A., Heidemann, M., Flatley, A., Imhof, A., Gut, M., et al. (2015). Site-specific methylation and acetylation of lysine residues in the C-terminal domain (CTD) of RNA polymerase II. *Transcription* 6, 91-101.

Vossenaar, E.R., Zendman, A.J., van Venrooij, W.J., Pruijn, G.J., (2003). PAD, a growing family of citrullinating enzymes: genes, features and involvement in disease. *Bioessays*. 25, 1106-18.

Wang, Y., Wysocka, J., Sayegh, J., Lee, Y.H., Perlin, J.R., Leonelli, L., Sonbuchner, L.S., McDonald, C.H., Cook, R.G., Dou, Y., et al. (2004). Human PAD4 Regulates Histone Arginine Methylation Levels via Demethylation. *Science* 306, 279-283.

Waterhouse, A.M., Procter, J.B., Martin, D.M., Clamp, M., Barton, G.J. (2009). Jalview Version 2--a multiple sequence alignment editor and analysis workbench. *Bioinformatics* 25, 1189-119.

Witalison, E.E., Thompson, P.R., Hofseth, L.J. (2015). Protein Arginine Deiminases and Associated Citrullination: Physiological Functions and Diseases Associated with Dysregulation. *Curr. Drug Targets*. 16, 700-710.

Wright, R.H., Castellano, G., Bonet, J., Le Dily, F., Font-Mateu, J., Ballaré, C., Nacht, A.S., Soronellas, D., Oliva, B., Beato, M. (2012). CDK2-dependent activation of PARP-1 is required for hormonal gene regulation in breast cancer cells. *Genes Dev.* 26, 1972-1983.

Xu, S., Grullon, S., Ge, K., Peng, W. (2014). Spatial clustering for identification of ChIP-enriched regions (SICER) to map regions of histone methylation patterns in embryonic stem cells. *Methods Mol Biol* 1150, 97-111.

Zaborowska, J., Egloff, S., Murphy, S. (2016). The pol II CTD: new twists in the tail. *Nat. Struct. Mol. Biol.* 23, 771-777.

Zeitlinger, J., Stark, A., Kellis, M., Hong, J.W., Nechaev, S., Adelman, K., Levine, M., Young, R.A. (2007). RNA polymerase stalling at developmental control genes in the *Drosophila melanogaster* embryo. *Nat. Genet.* 39, 1512-6.

Zhang, X., Bolt, M., Guertin, M.J., Chen, W., Zhang, S., Cherrington, B.D., Slade, D.J., Dreyton, C.J., Subramanian, V., Bicker, K.L., et al. (2012). Peptidylarginine

deiminase 2 catalyzed histone H3 arginine 26 citrullination facilitates estrogen receptor  $\alpha$  target gene activation. *Proc. Natl. Acad. Sci. U.S.A* *109*, 13331-6.

Zhang, Y., Zhou, L., Leng, Y., Dai, Y., Orlowski, R.Z., Grant, S. (2017). Positive transcription elongation factor b (P-TEFb) is a therapeutic target in human multiple myeloma. *Oncotarget* *8*, 59476-59491.

Zhang, Y., Liu, T., Meyer, C.A., Eeckhoute, J., Johnson, D.S., Bernstein, B.E., Nusbaum, C., Myers, R.M., Brown, M., Li, W. et al. (2008). Model-based analysis of ChIP-Seq (MACS). *Genome Biol.* *9*, R137.

Zhao, D.Y., Gish, G., Braunschweig, U., Li, Y., Ni, Z., Schmitges F.W., Zhong, G., Liu, K., Li, W., Moffat J., et al., (2016). SMN and symmetric arginine dimethylation of RNA polymerase II C-terminal domain control termination. *Nature* *529*, 48-53.

Zhu, L.J., Gazin, C., Lawson, N.D., Pagès, H., Lin, S.M., Lapointe, D.S., Green, M.R. (2010). ChIPpeakAnno: a Bioconductor package to annotate ChIP-seq and ChIP-chip data. *BMC Bioinformatics* *11*, 237.

## MAIN FIGURE TITLES AND LEGENDS

### **Figure 1 (With related Figure S1). Citrullination of R1810 at RNAP2-CTD. (A).**

*Top*: the epitope within repeats 31/32 of the CTD domain of RNAP2 used to generate  $\alpha$ -Cit1810. *Bottom*: duplicated western blot of T47D nuclear extract with  $\alpha$ -Cit1810 and  $\alpha$ -total-RNAP2. Line on the left mark the migration of the 250 kDa size marker.

**(B).** Extracts from T47D cells expressing  $\alpha$ -amanitin resistant WT<sup>r</sup> or R1810A<sup>r</sup> mutant of RNAP2 were precipitated with  $\alpha$ -HA antibody and probed with  $\alpha$ -Cit1810 or  $\alpha$ -RNAP2. **(C).** Representative super-resolution images of T47D cells immunostained with  $\alpha$ -Cit1810 (red) in combination with  $\alpha$ -total-RNAP2 (green),  $\alpha$ -S2P-RNAP2 (green) and  $\alpha$ -S5P-RNAP2 (green). **(D)** Plot representing the mean Pearson correlation coefficient of individual cells for  $\alpha$ -Cit1810-RNAP2 with  $\alpha$ -total-RNAP2 (n=22),  $\alpha$ -S2P-RNAP2 (n=24) and  $\alpha$ -S5P-RNAP2 (n=24); values presented as the mean  $\pm$  SEM. \*\* p-value < 0.005; ° p-value > 0.05.

### **Figure 2 (With related Figure S2). PADI2 citrullinates R1810 at RNAP2-CTD. (A)**

Bar plot showing the normalized reads of *PADI* gene family members from two RNA-sequencing experiments performed in T47D cells. The normalized reads are represented relative to *ACTB1* gene. Values are means  $\pm$  SEM. Inset-western blots performed on T47D nuclear extract with antibodies to PADI2, 3, 4 and Tubulin. **(B)** Nuclear extracts from T47D cells transfected with siRNA control (siCTRL) or siRNA against PADI2

(si*PADI2*) are probed with  $\alpha$ -Cit1810,  $\alpha$ -total-RNAP2,  $\alpha$ -PADI2 and  $\alpha$ -PADI3. (C) *Top*: Coomassie blue staining of SDS-PAGE with recombinant GST-tagged, GST-N-CTD and GST-C-CTD proteins used for the citrullination assay. *Bottom*: *In vitro* citrullination immunoblot with or without recombinant PADI2 (rPADI2) using as substrate the N-terminal half of the CTD containing R1603 (*lanes 3 & 4*) or the C-terminal half containing R1810 (*lanes 5 & 6*), both linked to GST. As a control, GST was also tested (*lanes 1 & 2*). (D) Microscale thermophoresis assay showing the affinity of recombinant PADI2 for the indicated wild -type and modified CTD-RNAP2 peptides encompassing the R1810. Y-axis represents the binding affinity as normalized fluorescence ( $F_{norm}$ , see methods). (E-F) Immunoprecipitation with (E)  $\alpha$ -PADI2 (F)  $\alpha$ -S2P/S5P RNAP2 or non-immune mouse or rabbit IgG of T47D extracts followed by western blot with the indicated antibodies.

**Figure 3 (With related Figure S3). PADI2 mediated cit1810 at RNAP2-CTD regulates transcription and cell proliferation in breast cancer cells.** (A) Volcano plot showing genome-wide mRNA changes after PADI2 depletion from biological replicates. The X-axis represents log<sub>2</sub> expression fold changes (FC) and the Y-axis represents the adjusted p-values (as -log<sub>10</sub>). Differentially expressed genes (FC > 1.5 or <1/1.5 and p value < 0.01) are shown, the positions of *PADI2* and genes used for validation are also indicated. (B) Quantitative RT-qPCR validation in T47D cells transfected with siCTRL, si*PADI2* and si*PADI3*. Changes in mRNA levels were normalized to *GAPDH* mRNA. Data represent mean  $\pm$  SEM of at least three biological experiments as in other plots in the figure. (C) Volcano plot showing genome-wide chromatin associated RNAs changes before and after PADI2 depletion from independent replicates. The X-axis represents the log<sub>2</sub> fold changes (FC) and the Y-axis represents the adjusted p values (-log<sub>10</sub>). The dotted line indicates the cutoff p value < 0.01. Differential expressed genes (FC > 1.5 or 1/1.5 and the p value < 0.01) are shown. (D) Browser snapshots of *SERPINA6* gene in T47D cells showing chromatin associated RNAs sequencing profile (orange) and mRNA sequencing profiles after *PADI2* knockdown (blue) and expressing WT<sup>r</sup> and R1810<sup>r</sup> mutant form of RNAP2 (Green). Scale is indicated on the top of the gene. (E) Quantitative RT-qPCR on chromatin associated RNA (ChrRNA) in T47D cells transfected with siCTRL, si*PADI2* RNAs. Data normalized to *GAPDH* ChrRNA expression level. (F) T47D cells expressing only



$\alpha$ -amanitin resistant HA tagged WT<sup>r</sup> or R1810A<sup>r</sup> mutant form of RNAP2 were used for quantitative RT-qPCR of mRNA from PADI2 dependent genes (*SERPINA6*, *c-MYC* and *HMGNI*), and for control genes (*GSTT2* and *LRRC39*). **(G)** Cell proliferation of T47D cells in the absence (siCTRL or DMSO) or presence of PADI2 depletion (siPADI2), PADI2 inhibitor (Cl-amidine in DMSO) and of cells expressing  $\alpha$ -amanitin resistant HA tagged WT<sup>r</sup> and R1810A<sup>r</sup> mutant form of RNAP2. **(H) Left:** Venn diagram showing the set of genes related to cell cycle (GO:0007049 (n= 315, Out of them 282 genes expressed in T47D cells) that are down-regulated in T47D cells expressing the R1810A<sup>r</sup> mutant of RNAP2 in comparison to WT<sup>r</sup> RNAP2 (R1810 dependent) versus R1810 independent gene (see **Table S2**). **Right:** Box plot showing log2 fold change (R1810A<sup>r</sup> / WT<sup>r</sup> RNAP2) for R1810 dependent and independent cell cycle genes. Each box in the panel represents the interquartile range; Whisker extends the box to the highest and lowest values, horizontal lines indicate the median value. Dependent genes showed significant lower mRNA levels than independent genes (\*\*\*p-value < 0.0001, calculated by Wilcoxon-Mann-Whitney test).

**Figure 4 (With related Figure S4). PADI2 occupancy on active genes.** **(A) Left:** Spie chart showing the distribution of PADI2 ChIP-seq peaks over various genomic regions. A dashed curved line indicates the region from 3kb upstream of TSS to 3kb downstream of TTS (or Polyadenylation site); the numbers in parenthesis show the proportion occupied by each region in the genome. **Right:** Enrichment of normalized PADI2 reads in various genome regions relative to random distribution (\* p-value <10<sup>-2</sup>; \*\* p-value <10<sup>-3</sup>; \*\*\* p-value <10<sup>-4</sup>). **(B)** Distribution of normalized PADI2 reads around the center of RNAP2 peaks in T47D cells. **(C)** RNAP2 and PADI2 occupancy across genes classified with increasing levels of expression. p-value was calculated by Wilcoxon-Mann-Whitney test in comparison to silent genes as indicated (\*\* p-value < 10<sup>-3</sup>; \*\*\* p-value < 10<sup>-5</sup>).

**Figure 5 (With related Figure S5). Cit1810 at CTD-RNAP2 regulates pausing in breast cancer cells.** **(A)** RNAP2 ChIP qPCR assay performed in T47D cells expressing only the HA-tagged wild-type (WT<sup>r</sup>) or R1810A<sup>r</sup> mutant of RNAP2 with the HA antibody. Non-immune IgG was used as negative control. Y-axis: fold change over the input samples. **(B-C)** Difference in RNAP2 density in T47D cells expressing HA-tagged R1810A<sup>r</sup> mutant versus WT<sup>r</sup> RNAP2 **(B)** across genes classified by expression.

(C) Pausing index of RNAP2 as indicated. (D-E) PADI2 dependent genes (n=2,186) showing (D) *Left*: average profile of difference in RNAP2 density (R1810A<sup>r</sup> - WT<sup>r</sup>) around TSS. *Right*: heat map at TSS of genes ranked from highest to lowest RNAP2 density (R1810A<sup>r</sup> - WT<sup>r</sup>). (E) Higher pausing index in cell expressing R1810A<sup>r</sup> mutant as compared to WT<sup>r</sup> form of RNAP2. (F) Browser snapshots showing RNAP2 occupancy for *HMGNI* & control gene *LRRC39* in cells expressing HA-tagged WT<sup>r</sup> or R1810A<sup>r</sup> form of RNAP2.

**Figure 6. Cit1810 at RNAP2-CTD is recognized by P-TEFb.** (A) Immunoprecipitation with  $\alpha$ -CDK9 (*Left*)  $\alpha$ -PADI2 (*Right*) or non-immune rabbit IgG of T47D extracts followed by western blot with the indicated antibodies. (B) Extracts from T47D cells in the presence (siCtrl) or absence (siPADI2) of PADI2 were immunoprecipitated with  $\alpha$ -total-RNAP2 followed by western blot for the indicated antibodies along with relative quantifications underneath. (C-D) Immunoprecipitation of extracts from (C) T47D (D) Raji cells expressing only the HA-tagged  $\alpha$ -amanitin resistant WT<sup>r</sup> or R1810A<sup>r</sup> mutant of RNAP2 were precipitated with  $\alpha$ -HA antibody and probed with the indicated antibodies. The relative quantification is shown underneath each gel. (E) (*Top*) Schematic representation of the pull-down assays with T47D nuclear extracts and RNAP2-CTD biotinylated peptides (wild type R1810 or cit1810). (*Bottom*) Results of the pull-down experiments with wild type (R1810) or cit1810 biotinylated RNAP2-CTD peptides shown as western blots probed with the indicated antibodies against CDK9 and CCNT1. Quantification of the increase with the Cit1810 relative to the wild type R1810 is shown underneath. (F) Average profile of CDK9 density around TSS in ChIP-seq experiments using CDK9 antibody in T47D cells expressing the HA-tagged wild-type (WT<sup>r</sup>) or R1810A<sup>r</sup> mutant of RNAP2 and difference (R1810A<sup>r</sup> - WT<sup>r</sup>) across genes classified by expression level. Black line representing signal difference from random regions. (G) *Left panel*: Similar as in (F) for PADI2 dependent genes versus nondependent genes (siPADI2/siCTRL, FC<1.5; FC>1/1.5, p-value > 0.05). *Right panel*: Box plot showing average difference in CDK9 profiles in PADI2 dependent versus non-dependent genes. p-value calculated by Wilcoxon-Mann-Whitney test. (H) Fold change over input in CDK9-ChIP qPCR assay on the promoter region of three PADI2 dependent genes (*SERPINA6*, *c-MYC*, *HMGNI*) and two non-dependent genes (*GSTT2*, *LRRC39*) in T47D cells expressing the HA-

tagged wild-type (WT<sup>r</sup>) or R1810A<sup>r</sup> mutant of RNAP2. Values are means  $\pm$  SEM. \* p-value < 0.05; \*\* p-value < 0.01; ° p-value > 0.05.

**Figure 7 (With related Figure S6-S7). Illustration of structural model of PADI2 with R1810 at RNAP2-CTD.** (A) Close-up of the peptide binding site of PADI2 shown in cartoon and surface representation (green) and R1810 CTD- RNAP2 peptide in ribbon (magenta) and stick representation of side-chains (colored by atom type: Oxygen: red; Nitrogen: blue; C: grey) of amino acid selected for mutation studies: non-conserved (ARG580, LEU642, shown in orange) and conserved (ASP374, SER401, shown in blue). (B) Box-plot showing the distribution of Rosetta Scores for the top 200 structural models performed for PADI2 and PADI3 proteins complexed with R1810 peptide. Central horizontal lines in the box mark the median and box edges of the first (Q1) and third (Q3) quartiles; top and bottom errors bars mark the Q1 and Q3 +1.5x interquartile range respectively; outliers are shown as empty circles. (C) *In vitro* citrullination immunoblot using the C-terminal CTD half containing R1810 as substrate, in absence (lane 2) or presence of recombinant PADI2 as wild-type (WT, lane 2) and PADI2 mutants of conserved residues (D374K and S401A lane 3 and 4) and of PADI2 unique residues (R580E and L642T, lane 5 and 6). (D) Proposed model of Cit1810 function in transcription. PADI2 catalyzed R1810 to the Cit1810 at RNAP2-CTD, facilitate association with P-TEFb (CDK9-CCNT1) complex and hence overcome RNAP2 accumulation and leads to an increase in transcription and cell proliferation.

## CONTACT FOR REAGENT AND RESOURCE SHARING

Further correspondence and requests for reagents should be directed to and fulfilled by the Lead Contact Miguel Beato ([miguel.beato@crg.eu](mailto:miguel.beato@crg.eu)).

## EXPERIMENTAL MODEL AND SUBJECT DETAILS

### Cell lines

T47D, MCF, and Raji cells were grown routinely in their optimal medium according the ATCC recommendations. T47D cell line carrying a single copy of luciferase reporter gene driven by MMTV promoter (T47D-MTVL, Truss et al., 1995) were grown in RPMI-1640 medium without phenol red supplemented with 10% dextran coated charcoal treated FBS (DCC/FBS), 2mM L-glutamine, 100U/ml penicillin-streptomycin as reported previously (Vicent et al., 2009; Wright et al., 2012). MCF7 cells were grown in DMEM (without phenol red) with 10% DCC/FBS and 100U/ml penicillin-

streptomycin. All cell transfections were carried out using Lipofectamine 3000 (Invitrogen) according to manufacturer's instructions. Cells were treated with 200 $\mu$ M citrulline inhibitor Cl-amidine (506282, Calbiochem) or vehicle (DMSO) for 2 hours. T47D cells (2.5 $\times 10^6$  cells per 8 $\mu$ g plasmid) were transiently transfected with HA tagged  $\alpha$ -amanitin resistant wild-type (WT<sup>r</sup>) or R1810A<sup>r</sup> RNAP2 plasmids for 24 hours followed by  $\alpha$ -amanitin (A2263, Sigma Aldrich, 6 $\mu$ g/ml) treatment for 12 hours to inhibit endogenous RNAP2.

Raji cells with stable expression of HA tagged WT<sup>r</sup> or R1810A<sup>r</sup> RNAP2 plasmids DNA were generated by electroporation (condition 250V and 950 $\mu$ F; 2 $\times 10^7$  cells per 10 $\mu$ g plasmid DNA) followed by selection with G418 (000000004727878001, Sigma Aldrich, 1mg/ml) and Doxycycline (D9891, Sigma Aldrich, 0.1 $\mu$ g/ml). To induce the expression of recombinant RNAP2 cells were grown in tetracycline-free complete medium for 48 hours prior to doxycycline (D9891, Sigma Aldrich) addition at a concentration of 0.1 $\mu$ g/ml. Endogenous RNAP2 was subsequently inhibited using  $\alpha$ -amanitin (2 $\mu$ g/ml) for 24 hours before downstream assays.

## METHODS DETAILS

### Experimental procedures

#### Antibodies

**Generation of anti-Cit1810 RNAP2-CTD Antibody:** The citrulline specific antibody was raised in rabbits by Eurogentec using a KLH coupled CTD peptide sequence (YSPSSP-cit-YTPQSP). Affinity purification was performed first on a column containing the citrullinated peptide, followed by removal of non-citrullinated specific antibodies on a column containing the non-citrullinated peptide.

Commercial antibodies used in this study were as follows: anti-PADI2 for ChIP and Immunoprecipitation assays : (sc-133877 lot no # E1214 and H0715, Santa Cruz Biot.); anti-PADI2 for western blots and Immunofluorescence (12110-1-AP from Proteintech and WH0011240M1 from Sigma); anti-citrulline (AB5612, Millipore), anti-citrulline detection kit (17-347, Millipore), anti-CARM1 (09-818, Millipore), anti-PRMT5 (07-405, Millipore), anti-TUBULIN (T9026, Sigma ), anti-GAPDH (sc-32233, Santa Cruz Biot.), anti-PADI4 (ab50247, Abcam), anti-PADI3 (sc-393622, Santa Cruz Biot), anti-HA (ab9110, Abcam), anti-RNAP2 for ChIP (CTD4H8,05-623, Millipore; Rpb1 NTD (D8L4Y), 14958, Cell Signaling), for western blot (N-20, sc-899, Santa Cruz Biot.), anti-phospho-S2 RNAP2 CTD (3E10, 04-1571 from Millipore), anti-CDK9 (H-169, SC-8338, lot no # C0415), anti-CCNT1(A303-499A, Bethyl Labs), IgG negative control for ChIP and immunoprecipitation assays (12-371, Millipore; 2729S Cell Signalling). Anti-S2P-RNAP2 (CMA602, MBL Life science) and anti-S5P-RNAP2 (CMA603, MBL Life science) were kindly provided by Hiroshi Kimura's laboratory.

**Peptides:** All peptides were synthesized and purified by Eurogentec. The CTD peptide PSYS<sub>2</sub>PSS<sub>5</sub>PRYT<sub>2</sub>PQS<sub>5</sub>PTYT<sub>2</sub>P was used for dot blots, and microscale thermophoresis (MST) experiments, either unmodified (CTD-WT) or with Cit1810, R1810me2a, S2-P (1805,1812,1819) or S5-P (1808, 1815) modifications. The N-terminal biotin labeled CTD peptides (CTD-WT with R1810) PSYS<sub>2</sub>PSS<sub>5</sub>PRYT<sub>2</sub>PQS<sub>5</sub>PTYT<sub>2</sub>P and (CTD-

cit1810) PSYS<sub>2</sub>PSS<sub>5</sub>PcitYT<sub>2</sub>PQS<sub>5</sub>PTYT<sub>2</sub>P were used for pull down assay. Peptides were quantified by amino acid analysis, and the presence of the modifications was confirmed by mass spectrometry.

**Plasmids:** The  $\alpha$ -amanitin resistant HA-tagged wild-type (WT<sup>r</sup>) or R1810A<sup>r</sup> mutant RNAP2 plasmids were previously published (Meininghaus et al., 2000; Sims et al. 2011). The GST-N-CTD (repeats 1-25.5), the GST-C-CTD (repeats 27-52) of RNAP2 were kindly provided by David Bentley (Bentley et al., 1999).

**RNA interference experiments:** For siRNAs inhibition experiments T47D or MCF7 cells were transfected with 100 $\mu$ M siRNA using Lipofectamine 3000 (Invitrogen) for 72 hours according to manufacturer's instructions. SMARTpool On-target plus siRNAs for PADI2 (M-019485-01) and PADI3 (M-021051-01) from Dharmacon (Thermo Scientific). siRNAs for CARM1 (sc-44875), PRMT5 (sc-41073) and PADI4 (sc-61283) from Santa Cruz Biot.

**Chromatin RNA extraction:** Chromatin RNA from T47D cells transfected with either siCTRL or siPADI2 was prepared as described previously (Nojima et al., 2016). Briefly, T47D cells transfected with siCTRL or siPADI2 were lysed for 5 minutes in 4ml of ice-cold HLB+N [10mM Tris-HCl pH 7.5, 10mM NaCl, 2.5mM MgCl<sub>2</sub> and 0.5% (vol/vol) NP-40], followed by addition of 1ml of ice cold HB+NS buffer [10 mM Tris-HCl pH 7.5, 10mM NaCl, 2.5mM MgCl<sub>2</sub>, 0.5% vol/vol, NP-40 and 10% wt/vol sucrose]. Cell nuclei were collected by centrifugation at 1,400rpm for 5 minutes at 4°C, resuspended in 125 $\mu$ l of NUN1 buffer [20mM Tris-HCl pH 7.9, 75mM NaCl, 0.5mM EDTA and 50% vol/vol glycerol]. After addition of 1.2 ml of ice cold NUN2 buffer [20mM HEPES-KOH pH 7.6, 300mM NaCl, 0.2mM EDTA, 7.5mM MgCl<sub>2</sub>, 1% vol/vol NP-40 and 1M urea], samples were incubated on ice for 15 minute, mixing by vortexing every 3 minutes. The chromatin pellet was resuspended in HSB buffer [10mM Tris pH 7.5, 500mM NaCl and 10mM MgCl<sub>2</sub>] and treated with TURBO™ DNase (AM2239, Thermo Scientific) at 37°C for 15 minutes, followed by Proteinase K (AM2546, Thermo Scientific) for 10 minutes at 37°C. Chromatin-RNA was purified by Trizol (Thermo Scientific), quantified with a Qubit 3.0 Fluorometer (Life Technologies).

**RNA extraction and RT-qPCRs:** RNA from T47D cells transfected with either siCTRL or siPADI2 and expressing  $\alpha$ -amanitin resistant HA-tagged wild-type (WT<sup>r</sup>) or R1810A<sup>r</sup> mutant RNAP2 was extracted using RNeasy (Qiagen) according to manufacturer's instructions. 1 $\mu$ g of purified RNA was used for DNase treatment (Thermo Scientific), quantified with a Qubit 3.0 Fluorometer (Life Technologies).

Reverse transcription was performed for chromatin RNA with random hexamers, for RNA with oligo (dT) using SuperScript III (Invitrogen) according to manufacturer's instructions. Complementary DNA was quantified by qPCR using Roche Lightcycler (Roche), as previously described (Vicent et al., 2009). For each gene product, relative RNA abundance was calculated using the standard curve method and expressed as relative RNA abundance after normalizing against the human *GAPDH* gene level. All the gene expression data generated by RT-qPCR represent the average and SEM of at least 3 biological replicates. Primers used for RT-qPCR are listed in **Table S4**.

## PolyA RNA-seq

Purified RNA was analyzed on Bioanalyzer using an RNA Pico assay chip. PolyA plus RNA mRNA libraries were prepared using TruSeq Stranded RNA Library Prep Kit (Illumina) and sequenced using Illumina HiSeq 2500.

### **Chromatin RNA-seq**

Chromatin associated RNA was prepared as mentioned above (Nojima et al., 2016). Before preparing chromatin RNA libraries, contaminant of rRNAs was depleted using Ribo-Zero rRNA removal kit. Libraries were prepared using TruSeq Stranded small RNA Library Prep Kit (Illumina) and sequenced using Illumina HiSeq 2500.

**Protein extract preparation, Co-immunoprecipitation (IP), Peptides pull down, and Western blots:** Cells were prepared as described previously (Wright et al., 2012). Briefly,  $5 \times 10^6$  to  $10^7$  cells were lysed on ice for 30 minutes in lysis buffer (1% Triton X-100 in 50mM Tris pH 7.4-7.6, 130mM NaCl) containing proteases inhibitors (11836170001, Roche) with rotation, followed by sonication for 7 minutes with every 30 seconds on and 30 seconds off. After centrifugation at 4°C and 13,000rpm for 10 minutes, extracts were used for protein quantitation. For IP 2mg of extract were incubated for 12 hours with protein G/A agarose beads (for rabbit antibodies, IP05, Millipore) or Dynabeads™ M-280 Sheep Anti-Mouse IgG (for mouse antibodies, 11201D, Thermo Scientific), previously coupled with 5-7µg of the corresponding antibodies or a control IgGs. For RNAP2-S2P and -S5P 7µg of each mouse monoclonal antibodies (CMA602 or CMA603, respectively) were coupled with Dynabeads, followed by 12 hours' incubation with extract at 4°C. The samples were washed 6 times with lysis buffer and boiled for 5 minutes in SDS gel sample buffer. For detection of mentioned proteins of molecular weight (<200 kDa) 4-12% SDS-PAGE gels were used; while for the RNAP2 large subunits (> 200kDa), we used 3-8% SDS-PAGE.

For peptide pull down assay, 100µg of each CTD-WT (with R1810) and CTD-cit1810 biotin labeled peptides were bound to 100µl of the Dynabeads™ MyOne™ Streptavidin T1 (65601, Thermo Scientific) in 1ml of binding buffer [150 mM NaCl, 50 mM Tris pH 8, 1% IGEPAL CA-630] by rotation at room temperature for 2 hours. The peptide bound Dynabeads were incubated with 300µg of T47D cells nuclear extract for 12 hours' at 4°C along with rotation. Peptide bound protein complexes were then washed five times with wash buffer [400 mM NaCl, 50 mM Tris pH 8, 1% IGEPAL CA-630] followed by two washes with binding buffer. All buffers were supplemented with freshly prepared protease inhibitors. Samples were eluted by incubation at 70°C for 5 minutes in SDS gel sample buffer, followed by protein detection of mentioned proteins by western blots.

For Western blots primary antibodies were used at 1:250 to 1:1000 dilution (for α-cit1810; 1:50) and incubated overnight at 4°C, followed by an hour incubation with horseradish peroxidase conjugated anti-mouse (NA931V) or anti-rabbit (NA934V, Amersham) and blots were developed using ECL prime Western blotting detection reagent (RPN2232, GE Healthcare) according to the manufacturer instructions.

**Size exclusion chromatography:** The size exclusion chromatography of T47D cell extracts were carried out using Superdex 200 10/300mm columns (17517501, GE healthcare). As per manufacturer's instructions, for high molecular weight (Ferritin ,440 KDa) and for low molecular weight (Conalbumin,75 KDa & Carbonic anhydrase

29KDa) were run along with cell extracts. Samples were chosen according to chromatography profile and used for Western blots.

**BrdU (5'-bromo-2'-deoxyuridine) cell proliferation assay:** T47D cells ( $1 \times 10^4$ ) were plated in a 96-well plate followed by transfection with control/ PADI2 siRNAs or treated with the PADI inhibitor Cl-amidine at concentration of 200 $\mu$ M or DMSO or expressing  $\alpha$ -amanitin resistant HA-tagged wild-type (WT<sup>r</sup>) or R1810A<sup>r</sup> mutant form of RNAP2. The cell proliferation ELISA BrdU Colorimetric assay (Roche, 11647229001) was performed as per manufacturer's instructions. The experiments were performed at least four biological replicates.

**Fluorescence-activated cell sorting (FACS) experiments:** FACS assay was performed in T47D cells transfected with control or PADI2 siRNAs from three biological replicates. Briefly, cells were trypsinized, washed three times with 1x PBS and fixed with cold absolute ethanol in suspension at 70% final concentration. Cells were stained with propidium iodide (P-1304, Molecular Probe) followed by DNase I (RNase-free) (AM2222, Thermo Scientific) treatment and stored for 24 hours at 4°C and DNA contents of cell cycle phases were analyzed using a BD™ LSR II flow cytometer.

***In vitro* citrullination assay with recombinant PADI2 wild-type and mutants (D374K, S401A, R580E, and L642T) and fragments of the RNAP2-CTD:** The PADI2 open reading frame (ORF) was cloned into the HIS-tagged expression vector pCoofy1 (Addgene, 43974) and the wild-type (WT) plasmid sequence were verified. All four PADI2 mutants were generated by using WT PADI2 plasmid by performing site-directed mutagenesis as directed in Quick change mutagenesis kit and mutations were confirmed by sequencing. The mutagenic primers given in Key Resource Table.

Recombinant proteins were expressed in bacteria strain BL21 pRARE and purified following the standard method of histidine-tagged recombinant protein. Briefly, cells were lysed in Buffer A (50mM Tris HCl pH7.4, 500mM NaCl, 10% glycerol, 2mM DTT, 20mM Imidazole, 1% and triton X-100) complemented with proteinase inhibitors (11836170001, Roche). Purification was performed using the HiTrap TALON crude (28953766, GE Healthcare) according to manufacturer's instruction. Proteins eluted in buffer containing 50mM Tris-HCl pH 7.4, 300mM NaCl and 10% glycerol, were stored at -80°C until required. The GST-N-CTD (repeats 1-25.5), GST-C-CTD (repeats 27-52) of RNAP2 were expressed and purified following the standard glutathione bead purification (Bentley et al., 1999). *In vitro* citrullination was carried with recombinant His-PADI2 in deimination buffer (50mM HEPES pH 7.5, 10mM CaCl<sub>2</sub>, 4mM DTT) at 37 °C for 1hour. Samples were dissolved in sample Laemmli buffer for immunoblot analysis using an anti-citrulline antibody (Christophorou et al., 2014; Wang et al., 2004), Millipore, 17-347).

**Microscale Thermophoresis (MST) of recombinant PADI2 with RNAP2-CTD peptides:** Wild-type peptide or peptides carrying modifications of R1810me2a CTD, S2P-CTD and S5P CTD (20nM to 500 $\mu$ M) were titrated against a fixed concentration of fluorescent recombinant His-PADI2 (50nM). MST data were acquired at 20°C using the red LED at 20% and IR- Laser at 40% using a (Monolith NT.115, Nano Temper Technologies) according to manufacturer's instructions. The results are plotted as

normalized fluorescence ( $F_{\text{norm}}$ , representing binding affinity) against the concentration of the unlabeled ligand and fitted according to the law of mass action.

**Immunofluorescence, image acquisition and analysis:** T47D cells were grown on round 10mm glass coverslips transfected with sicontrol or si*PADI2* prior to fixation with 4% paraformaldehyde in PBS for 5 minutes and permeabilized with PBS 0.1% Triton X-100 (PBST) at room temperature for 5 minutes. Coverslips were blocked with IF buffer (5% BSA, 0.1% Triton X-100 in PBS) for 20 minutes at room temperature and incubated overnight with primary antibodies diluted in IF buffer at 1:50 of  $\alpha$ -Cit1810 (Rabbit), 1:50 of  $\alpha$ -CTD4H8 (mouse, Santa Cruz Biot.) to detect the total RNAP2, 1:250 of  $\alpha$ -S2P-RNAP2 (mouse, CMA602) and 1:250 of  $\alpha$ -S5P-RNAP2 (mouse, CMA603). For triple staining 1:500 of  $\alpha$ -PADI2 (Mouse, WH0011240M1, Sigma) was used with 1:50 of  $\alpha$ -Cit1810 along with  $\alpha$ -S2P-RNAP2 (3E10; Rat, Millipore; **Figure S2I**). For **Figure S1G**,  $\alpha$ -HA (1:250, ab9910; Rabbit) and  $\alpha$ -RNAP2 (1:50, CTD4H8; mouse, Santa Cruz Biot.). After 3x washes with PBST (1X PBS with Triton X-100 0.1 %) samples were incubated with secondary antibodies at a dilution 1:500 (AlexaFluor 594 anti-rabbit, AlexaFluor 488 anti-mouse or AlexaFluor 680 anti-mouse and AlexaFluor 488 anti-rat, Invitrogen-Molecular Probes) for 1h at room temperature followed by three washes with PBST. Samples were mounted with Mowiol mounting medium. For quantification, DAPI (4', 6-Diamidino-2-Phenylindole, Dihydrochloride) or Hoechst fluorescent stains were used as reference. Confocal images of T47D cells (**Figure S1G and Figure S2B**) were acquired with a Leica SP5 (DMI 6000) inverted microscope using an HCX PLAN APO  $\lambda$  blue 63x/1.4-0.6 Oil immersion lens, PMT detectors and diode and Argon lasers. Laser and spectral detection bands were chosen for the optimal imaging of Alexa 488, Alexa 594 and DAPI to obtain Z-stacks of nuclear optical sections at a distance of 0.42 $\mu$ m.

Super-resolution images were acquired with a Leica SP8 STED 3X microscope using a HC PL APO CS2 100x/1.4 Oil immersion lens, a pulsed supercontinuum light source (white light laser) and HyD detectors, using the Leica acquisition software. Laser and spectral detection bands were chosen for the optimal imaging of nuclear optical sections with a z-distance of 0.16 $\mu$ m. Deconvolution was performed using the Huygens deconvolution software (Scientific Volume Imaging, SVI) for STED modes using shift correction to account for drift during stack acquisition. Adjustments of individual channels were applied to the whole image, pseudo-coloring, cropping and different channel composite images were done with FIJI (<https://www.fiji.sc>, Schindelin et al. 2012 ). Raw cropped images were used to calculate the correlation of the fluorescent signal with R version 3.4.1 (<https://www.R-project.org/> R core team, 2017). All images were imported to the R with the package EBImage (Pau et al., 2010).

**ChIP-qPCRs:** For ChIP assays (Vicent et al. 2014),  $10 \times 10^6$  of T47D cells, transfected with either si*CTRL* or si*PADI2* and expressing  $\alpha$ -amanitin resistant HA-tagged wild-type (WT<sup>r</sup>) or R1810A<sup>r</sup> mutant RNAP2 were cross-linked for 10 minutes with 1% formaldehyde. The lysate was sonicated to a DNA fragment size range of 200-300bp using a Biorupter sonicator (Diagenode). PADI2 was immunoprecipitated with 6 $\mu$ g of PADI2 antibody (z-22):sc-133877 lot number E1214 and H0715 using 50  $\mu$ g of chromatin and 42 $\mu$ l of Protein A-Agarose Beads (Diagenode). For RNAP2, 150  $\mu$ g chromatin was incubated with 20 $\mu$ g of antibody (Rpb1 NTD (D8L4Y), 14958, Cell Signaling; CTD4H8, Millipore), 15 $\mu$ g of anti-HA (ab9110) for HA-tagged wild-type (WT<sup>r</sup>) or R1810A<sup>r</sup> mutant form of RNAP2, 15 $\mu$ g of anti-CDK9 (H-169, SC-8338, lot



no # C0415), 20µg of S2P; CMA602 and S5P; CMA603) or control IgG in IP Buffer with 2X SDS buffer (100mM NaCl, 50mM TrisHCl, pH8, 5mM EDTA and 0.5% SDS) and 1X Triton buffer (100mM Tris-HCl, pH8.8, 100mM NaCl, 5mM EDTA and 5% Triton-X) with protease inhibitors (11836170001, Roche) for 16 hours at 4° C. Followed by incubating with Protein A Sepharose beads CL-4B (17-0780-01, GE Healthcare) or 50µl of Dynabeads® M-280 sheep anti-mouse IgG (11201D, Thermo Scientific) for 3 hours. Beads were washed with 3 times with low salt buffer (140mM NaCl, 50mM HEPES, pH 7.4, 1% Triton-X 100), 2 times with high salt buffer (500 mM NaCl, 50mM HEPES, pH 7.4, 1% Triton-X 100) followed by single wash of LiCl Buffer (10mM Tris HCl pH 8.0, 250 mM LiCl, 1% NP-40, 1% sodium deoxycholic acid and 1mM EDTA) and 1X TE buffer in cold room. Subsequently, crosslinks were reversed at 65° C overnight, followed by RNAase treatment for 1.5 hours and bound DNA was purified by Phenol-Chloroform extraction. The resultant eluted DNA was quantified by Qubit 3.0 Fluorometer (Life technologies), and followed by real-time qPCR analysis and data represented as fold change over input fraction from at least 3 biological replicate experiments. Primers used for RT-qPCR are listed in **Table S4**.

### ChIP-seq

PADI2 and RNAP2 ChIP-purified DNA were analyzed on Bioanalyzer using DNA1000 kit. At least 1ng of purified DNA were used to prepare ChIP-seq libraries using Illumina ChIP Sample Library Preparation Kit. End repaired and adapter ligated libraries samples were size selected using E-Gel Size Select 2% Agarose Gel (Thermo Scientific, USA) followed by 13 cycles of PCR amplification. Barcode libraries from several samples were pooled and sequenced using Illumina HiSeq 2000 in single end sequencing run to obtain ~80–100 million reads.

### Bioinformatic Procedures

#### RNA-seq Data processing

Adapter sequences were removed from raw paired-end reads PolyA plus mRNA and ChrRNA raw paired-end reads by using Trimmomatic (Bolger et al. 2014) with the parameter values single-end mode, seed mismatches = 2, palindrome clip = 30, simple clip threshold = 12, min adapter length = 1, keep both reads, leading = 3, trailing = 3, target length = 0, strictness = 999 and min length = 36. Transcript-level quantification was performed by Kallisto (Bray et al. 2016) by using 100 bootstraps. Spearman pairwise correlation ( $R^2$ ) between the two biological replicates (E1 and E2) were calculated, for the mRNA-sequencing siCTRL ( $R^2=0.96$ ), siPADI2 ( $R^2=0.97$ ), WT<sup>r</sup> ( $R^2=0.98$ ) and R1810A<sup>r</sup> ( $R^2=0.97$ ) and for the ChrRNA-sequencing experiments siCTRL ( $R^2=0.95$ ) and siPADI2 ( $R^2=0.93$ ).

#### Gene Expression Analysis

Differential expression analysis was performed using DESeq2 Bioconductor package (Love et al., 2014). The analysis was performed by using 196,520 number of annotated transcripts of hg19 (correspond to 57,280 number of genes). Out of this, we quantitated

data for total 18,241 (mRNA seq) and 33,140 (ChrRNA seq) genes. Genes with  $FC < 1.50$  and adjusted p-value  $< 0.01$  were considered as down-regulated and genes with  $FC > 1.50$  and adjusted p-value  $< 0.01$  as up-regulated (**Figure 3A and 3C**).

### ChIP-seq Data processing

For ChIP-Seq data sets, first we performed the quality control analysis using fastQC tool with version GPLV3 (<https://www.bioinformatics.babraham.ac.uk/projects/fastqc/>). Single-ended sequences were trimmed to 50 bp and mapped to the human genome assembly hg19 using Bowtie (Langmead et al. 2009), keeping only tags that mapped uniquely and with no more than two mismatches. Fragment sizes were estimated using HOMER tools (Heinz et al. 2010). Normalized coverage profiles for regions of interest were obtained by using deepTools2 (Ramírez et al. 2016) with a 100bp bin size.

RNAP2 and CDK9 ChIP-sequences were analyzed as mentioned previously (Iannone et al. 2015) by using MACS2 (Zhang et al. 2008) with a FDR q-value  $< 0.05$ . We noted that it typically results in regions with a very modest enrichment. Therefore, by default, we applied a more stringent threshold of FDR q-value  $< 0.0001$  and a 4-fold enrichment over the control sample to base the subsequent downstream analyses on a high-confidence set of peaks. Because of broad peak of PADI2, significant enrichment to background compared to Input DNA were identified using SICER (Xu et al. 2014) with the following parameters: window size 200; fragment size 233 bp; gap size 600; and FDR 0.01. Genome-wide 10kb Spearman pairwise correlation of PADI2 ChIP-sequencing signal was  $R^2 = 0.98$ . We then applied ChIPpeakAnno R library (Zhu et al. 2010) to create a merged list of peaks present in both replicates. ChIP-seq RPM normalized profiles were used to generate average profiles over different genomic features using bwtool (Pohl et al. 2014) deepTools2 (Ramírez et al. 2016) with a 100bp bin size. Similarly, ChIP-seq profiles from HA-tagged WT<sup>r</sup> and R1810A<sup>r</sup> were obtained by deepTools2 with 100bp bin size and their difference (R1810A<sup>r</sup>-WT<sup>r</sup>) was plotted by using in house custom R version 3.4.1 (R core team 2017) scripts on the indicates set of transcripts.

**Pausing Index (PI) of RNAP2 Analysis:** RNAP2 pausing index was calculated as mentioned previously (Baranello et al., 2016; Zeitlinger et al., 2007; Chen et al., 2015). Briefly, RNAP2 pausing index represents the dynamics of RNAP2 assembly and promoter release and hence not only presence or absence of transcription. We calculated pausing index (PI) as the ratio of the RNAP2 read count 1kb (kilobase) flanking to the TSS divided by size and read count in the same gene body divided by the size of the gene body.

**Gene Ontology (GO) analysis:** Go Annotation was performed using the online tool GSEA (Subramanian et al., 2005) (<http://software.broadinstitute.org/gsea/index.jsp> Gene Set Enrichment Analysis,) collection database v5. The significant cut off p-value and FDR q-value  $< 0.05$ . All 315 genes documented with the parent cell cycle GO:0007049 ([http://software.broadinstitute.org/gsea/msigdb/cards/CELL\\_CYCLE\\_GO\\_0007049](http://software.broadinstitute.org/gsea/msigdb/cards/CELL_CYCLE_GO_0007049)) were considered for analysis. Among them, 282 genes expressed in T47D cells; 101 genes classified as PADI2 dependent (siCTRL/siPADI2 FC  $< 1/1.5$ , p-value  $< 0.01$ ) and rest 181 genes as PADI2 independent (**Figure 3H and Table S1**).

## **Structural modeling of PADI2 and PADI3 with R1810 RNAP2-CTD complexes and conservation analysis.**

In the case of PADI2 (UniProt ID: Q9Y2J8), there are several crystallographic structures available in apo form in the PDB databank (Berman et al., 2000) and the one with PDB code 4N2I (Slade et al., 2015) was used to model the PADI2-R1810 RNAP2-CTD complex. The structure of the apo-form of PADI3 (UniProt ID: Q9ULW8) was derived by homology modeling using M4T (Fuentes et al., 2007). PADI2 (PDB code: 4N2G (Slade et al., 2015) was used as template sharing over 51% sequence identity with (coverage above 95%), hence optimal for homology modeling (Baker et al., 2001). The quality of the PADI3 model was assessed using ProSa2 (Sippl et al., 1993) and PROCHECK (Laskowski et al., 1993).

The structural models of PADI2 and PADI3 bound to RNAP2 CTD peptide encompassing R1810 (sequence: YSPSSPRYPQSPT) were derived using the pepspec application (King et al., 2010) in the Rosetta Suite (Fay et al., 2011) as follow. The structure of PADI4 in complex with histone H3 N-terminal tail (PDB code:2DEW, Arita et al., 2006) was used to position the central arginine of R1810 CTD RNAP2 peptides, i.e. anchor residue, both in PADI2 and PADI3 structures. 100 models were generated, selecting the one with the best score for the second part of the modeling process: peptide extension. The central anchor residue, i.e. Arginine, was extended both in Nt and Ct directions by adding one residue at a time to match the sequence of the RNAP2 CTD peptide. In total 5000 models were generated for both PADI2 and PADI3 bound to RNAP2 CTD peptide bearing R1810 residue and ranked according to Rosetta score (Fay et al., 2011).

The analysis of sequence conservation was done as follow. The sequences of PADI1 (UniProt ID: Q9ULC6), PADI2 (UniProt ID: Q9Y2J8), PADI3 (UniProt ID: W9ULW8), PADI4 (UniProt ID: Q9UM07) and PADI6 (UniProt ID: Q6TGC4) were aligned using ClustalW (Thompson et al., 1994). From the multiple sequence alignment, a conservation score, ranging from 0 to 10, was computed for each residue using JalView (Waterhouse et al., 2009; Livingstone et al., 1993).

## **QUANTIFICATION AND STATISTICAL ANALYSIS**

For super-resolution image analysis in Figure1D and Figure S2H, Pearson correlation was calculated for the fluorescent signal of the two channels of interest for each individual stack. Statistical analysis (two-tailed Student's t-test) for the average z-stack Pearson's correlation of each individual cell. For all experiments of RT-qPCR, ChIP-qPCR and cell proliferation, a Two-tailed unpaired Student's t-test was used to determine statistical significance between the groups. Plots and indicated statistical analysis were done with the use of Prism (GraphPad Prism 6.0 for MacOS), unless otherwise stated. Correction between biological replicated of RNA and ChIP-sequencing was calculated by Spearman's correlation (R2). For all other experiments, significance between groups calculated by Wilcoxon-Mann-Whitney test. If exact p-value are not shown or indicated in legend then p-values are represented in all figures as follows: \*, p-value  $\leq 0.05$ ; \*\*, p-value  $\leq 0.01$ ; \*\*\*, p-value  $\leq 0.001$ ; °, p-value  $> 0.05$ .

## DATA AND SOFTWARE AVAILABILITY

All high throughput sequencing data performed and used in this study have been deposited at GEO with accession code GSE105795.

## Supplementary Figure, Table and Movie Legends.

### Figure S1 (Related to Figure 1). Specificity of the anti-Cit1810 RNAP2 antibody

(A) T47D cells extracts immunoprecipitated with pan-citrulline antibody and analyzed by western blot using antibodies against total-RNAP2, S5 and S2 phosphorylated forms of RNAP2. The dotted line indicates a separate gel (see methods) and lines on the left mark the migration of the 250 kDa size marker. (B) Dot blot showing the specificity of  $\alpha$ -Cit1810, performed with 1, 0.2 and 0.04  $\mu$ g of mentioned RNAP2-CTD peptides encompassing R1810 with specific post-translational modifications. Only the peptide bearing the Cit1810 modification were specifically recognized by  $\alpha$ -Cit1810. (C) The specificity of  $\alpha$ -Cit1810 was also confirmed by the peptide competition assay.  $\alpha$ -Cit1810 was incubated with 2 $\mu$ g of each of the indicated peptides for 30 minutes at 4°C prior to probing the membrane with the Cit1810 peptide. (D) Duplicated western blot of T47D nuclear extract with  $\alpha$ -Cit1810 run on *Left*: 3-8% SDS PAGE and *Middle*: 4-12% SDS PAGE, *Right*: Ponceau S staining of the 4-12% SDS PAGE gel. Line on the side mark the migration of the protein size marker. (E) Titration of the concentration of  $\alpha$ -amanitin needed to deplete endogenous RNAP2 in T47D cells. Cells were incubated with increasing concentrations of  $\alpha$ -amanitin (0, 2, 4 and 6 $\mu$ g/ml; *lanes 1 to 4*) for 12 hours before preparing nuclear extracts. The extracts were probed in western blot with an antibody against total RNAP2; Tubulin was used as loading control. (F) Western blot of extracts from T47D cells depleted of endogenous RNAP2 by preincubation with 6 $\mu$ g/ml  $\alpha$ -amanitin, and transfected with empty vector (-) or with expression vectors for WT<sup>r</sup> or the R1810A<sup>r</sup> mutant HA-tagged recombinant RNAP2 carrying an additional mutation that makes the enzyme resistant to  $\alpha$ -amanitin (see Method). The western blots were probed with antibodies against the HA tag or total-RNAP2; Tubulin and GAPDH were used as loading control. (G) Immunofluorescence images of T47D cells using  $\alpha$ -HA (green) and  $\alpha$ -RNAP2 (red), depleted of endogenous RNAP2 by preincubation with 6 $\mu$ g/ml  $\alpha$ -amanitin, and transfected with either expression vectors for (*Left*) WT<sup>r</sup> or the (*Right*) R1810A<sup>r</sup> mutant HA-tagged recombinant RNAP2.

**Figure S2 (Related to Figure 2). PADI2 interacts with CTD-R1810 in vivo and in vitro.** (A) Western blot of extracts from T47D cells transfected with siRNA control (siCTRL) or siRNA against *PADI3* (siPADI3) and probed with the indicated antibodies. (B) Immunofluorescence image of T47D cells transfected with siCTRL (*upper panel*) or siPADI2 (*lower panel*) using  $\alpha$ -PADI2 (red) and  $\alpha$ -Cit1810(green) along with DAPI. (C) Western blot of extracts from MCF7 cells transfected with siCTRL or siPADI2 and probed with the indicated antibodies. (D) Western blot of extracts from MCF7 cells transfected with siRNA CTRL or siPADI4 and probed with the indicated antibodies. The total intensity of PADI4 and PADI2 band quantitated by Image J after PADI4 depletion and indicated underneath (siCTRL set to 1) (E-F) Immunoprecipitation of (E) T47D (F) MCF7 extracts with an  $\alpha$ -total-RNAP2 or with non-immune rabbit IgG followed by western blot with the indicated antibodies. (G) Immunoprecipitation of T47D extracts with  $\alpha$ -PADI2 or non-immune rabbit IgG probed with indicated antibodies. (H) Fractionation of T47D cells extract using a Superdex 200 gel filtration column and analysis of the eluted fractions by western blotted with the indicated antibodies. (I) *Left*: Representative super-resolution immunofluorescence images of T47D cells using triple labeling with  $\alpha$ -Cit1810 (red) in combination with  $\alpha$ -S2P-RNAP2 (green) and  $\alpha$ -PADI2 (blue). Plot representing the mean Pearson correlation coefficient of several individual cells (n=16), for PADI2 with Cit1810 (purple), for S2P-RNAP2 with Cit1810 (yellow) and for PADI2 with S2P-RNAP2 (cyan). *Right*: Person correlation coefficient presented a value of mean  $\pm$  SEM. Note Cit1810-RNAP2 showed co-localization with PADI2 as well as with S2P-RNAP2 (shown as white in the merged image).

**Figure S3 (Related to Figure 3). PADI2 depletion affects genes involved in cell cycle progression.** (A) Changes in *PADI2*, *PADI3* and *HMOX1* mRNA quantified by RT-qPCR in T47D cells transfected with siPADI2 (orange bars) or siPADI3 (grey bars). mRNA levels were normalized to a *GAPDH* mRNA expression level, which was not affected in these experimental conditions, and are presented as a ratio to levels in cells transfected siCTRL. Values are the mean  $\pm$  SEM of at least three biological replicates as in other plots in the figure. (B) Volcano plot showing indicated gene biotypes of differentially expressed genes determined from polyA-RNA sequencing as shown in

Figure 3A. The X-axis represents log<sub>2</sub> expression fold changes (FC) and the Y-axis represents the adjusted p-values (as -log<sub>10</sub>). **(C)** Gene set enrichment analysis (GSEA) for biological processes and molecular functions. Seven representative processes are presented. The X-axis shows the -log<sub>10</sub> transformed p-values. GO, Gene Ontology. **(D)** The mRNA-seq data validated by RT-qPCR for indicated genes. Y-axis shows the fold change over siCTRL, orange color indicates data from duplicate RNA-seq and green color from RT-qPCR (mean  $\pm$  SEM from at least three experiments). **(E)** Knockdown of *CARM1* mRNA (>80% depletion relative to siCTRL) did not significantly affect PADI-dependent gene transcripts. Data are shown as fold change over siCTRL and represent mean  $\pm$  SEM. Extracts from siCTRL and si*CARM1* transfected cells were probed with indicated antibodies to estimate CARM1 depletion (>80%). **(F)** Knockdown of *PRMT5* mRNA (>80% relative to siCTRL mRNA) did not significantly affect PADI-dependent gene transcripts. Extracts from siCTRL and si*PRMT5* transfected cells were probed with indicated antibodies to estimate PRMT5 depletion (>90%). **(G)** Browser snapshots of control *GSTT2* (related to **Figure 3D**) gene in T47D cells showing chromatin associated RNAs sequencing profile (orange) and mRNA sequencing profiles after *PADI2* knockdown (blue) and expressing WT<sup>r</sup> and R1810<sup>r</sup> mutant form of RNAP2 (Green). Scale is indicated on the top of the gene. **(H) Left:** Cell cycle profile of T47D cells transfected with siCTRL (black) and si*PADI2* (orange) obtained by propidium iodide labeling followed by fluorescence-activated cell sorting (FACS) analysis. **Right:** Histogram showing the percentage of cells during cell cycle phases. Data presented as mean  $\pm$  SEM from three biological replicates. p-value was calculated by student's t test, \* p-value < 0.05, \*\* p-value < 0.001. **(I) Left:** Venn diagram showing the set of genes related to cell cycle (GO:0007049 (n= 315, Out of them 282 genes expressed in T47D cells) down regulated in T47D cells after *PADI2* depletion (*PADI2* dependent) versus *PADI2* independent gene (see **Table S2**). **Right:** Box plot showing log<sub>2</sub> fold change (si *PADI2*/si CTRL) for *PADI2* dependent and independent cell cycle genes. Each box in the panel represents the interquartile range; Whisker extends the box to the highest and lowest values, horizontal lines indicate the median value. Dependent genes showed significant lower mRNA levels than independent genes (\*\*\*p-value < 0.0001, calculated by Wilcoxon-Mann-Whitney test). **(J)** Venn diagram representing the set of cell cycle genes dependent on *PADI2* and R1810 RNAP2-CTD (see **Table S2**). **(K)** Word cloud of all the *PADI2* dependent genes represented in **Figure S3I**; Size of genes indicates an extent of down-regulation after *PADI2* depletion as measured by the log<sub>2</sub>

fold change siPADI2/siCTRL.

**Figure S4 (Related to Figure 4). RNAP2 and PADI2 co-localize on highly transcribed genes. (A)** Browser snapshots representing the PADI2 and RNAP2 occupancy on highly transcribed genes *SERPINA6* and *HMGNI* versus lowly expressed genes (*GSTT2* and *LRRC39*). A scale is shown on the top for each gene. Y-axis: reads per million (RPM). **(B)** PADI2 occupancy monitored along the gene bodies by PADI2 ChIP assay in T47D cells transfected with siPADI2 or siCTRL followed by qPCR along the gene bodies of two highly transcribed genes (*SERPINA6*, *c-MYC*) and a low transcribed gene (*GSTT2*). Non-immune IgG was used as negative control. Y-axis: PADI2 enrichment over input samples. Data represented as mean  $\pm$  SEM from at least three biological replicates as in other plots of the figure. Top: basic gene structure and scale with the positions of the amplicons. **(C)** PADI2 ChIP-seq normalized reads in a window from 3kb upstream of TSS to 3kb downstream of TTS on genes down regulated and non-regulated genes after PADI2 depletion in mRNA-sequencing (*left*) and ChrRNA-sequencing (*right*). Down regulated genes showed significantly higher PADI2 recruitment both from mRNA-seq and ChrRNA-seq as indicated, p-value was calculated by Wilcoxon-Mann-Whitney test. Box represents the interquartile range; Whisker extends the box to the highest and lowest values. A line across each box indicate the median value. **(D)** RNAP2 ChIP followed by PADI2 re-ChIP assay performed in T47D cells to examine co-localization on promoter regions (A primer) and exons (B or C primers) of two highly transcribed genes (*SERPINA6*, *c-MYC*) and a low transcribed gene (*GSTT2*).

**Figure S5 (Related to Figure 5). PADI2 directed citrullination of R1810 regulates pausing of highly transcribed genes. (A-B)** RNAP2 ChIP qPCR performed in T47D cells after PADI2 depletion with an antibody to RNAP2 or in cells expressing only the HA-tagged wild-type (WT<sup>r</sup>) or R1810A<sup>r</sup> mutant of RNAP2 with the HA antibody. (A) Promoter region of PADI2 and R1810 dependent genes (*SERPINA6*, *c-MYC*, *HMGNI*) (B) Intragenic regions of PADI2 and R1810 dependent genes. Primers for intragenic regions were *SERPINA6*-C, *c-MYC*-B and *HMGNI*-B (**Table S4**). Non-immune IgG was used as negative control. Y-axis: fold change over the input samples. **(C)** S5P and S2P RNAP2 occupancy was monitored along the gene bodies by performing ChIP assay in T47D cells transfected with siCTRL or siPADI2 (*black or yellow*), or T47D cells expressing only WT<sup>r</sup> or the R1810A<sup>r</sup> mutant of RNAP2 (*grey or orange*) followed by

quantitative PCRs along the gene bodies. Y-axis: relative enrichment normalized to total RNAP2; values are means  $\pm$  SEM. *Top*: For each gene, the basic gene structure and the position of the amplicons are indicated. **(D)** Higher pausing index in the cell expressing R1810A<sup>r</sup> mutant as compared to WT<sup>r</sup> form of RNAP2 calculated for shared 939 genes down regulated after PADI2 depletion (2,186) and R1810 dependent (1392 genes found significantly down regulated by considering FC < 1/1.5 and p-value < 0.01, after expressing R1810A<sup>r</sup> mutant as compared to WT<sup>r</sup> RNAP2) in T47D. **(E-F)** Box plot of the pausing index of **(E)** top 25% down-regulated and up-regulated genes after PADI2 depletion from mRNA-seq (*left*) and ChrRNA-seq (*right*). **(F)** Down regulated (n=1392) and up regulated (n=1372) genes obtained from replicate mRNA-seq performed in T47D cells expressing R1810A<sup>r</sup> mutant as compared to WT<sup>r</sup> form of RNAP2. p-value was calculated by Wilcoxon-Mann-Whitney test. Each box represents the interquartile range; Whisker extends the box to the highest and lowest values. A line across each box indicate the median value.

**Figure S6 (Related to Figure 7). PADIs conservation homology analysis.** Ribbon representation of top ranking structural model of PADI2 bound to CTD-R1810 peptide. Residues colored according to its conservation among human PADIs (PADI1, PADI2, PADI3, PADI4 and PADI6) as shown in the conservation scale. *Inset*: Close up of the peptide binding side and selected residues shown in stick representation. R1810 shown as reference in ball and stick representation both in full size and close up. The partial alignments show each selected residue (LEU642 and ARG580 residues, non-conserved unique to PADI2, in orange color and ASP374 and SER401, residues not unique to PADI2, in blue color) and flanking regions with a histogram underneath showing the conservation among PADIs as indicated in scale.

**Figure S7 (Related to Figure 7). Identification of PADI2 unique residues for CTD-R1810 specificity.** **(A)** Box plot showing the distribution of energies decomposed (Y-axis) for each interface residue (X-axis) among the top 200 structural models of PADI2-CTD-R1810 peptide (**Table S3**). Residues are sorted by increasing conservation from left to right in the X-axis and labelled as follow: three letters residue type, residue number and conservation (between 0 to 10). box represents the interquartile range; Whisker extends the box to the highest and lowest values. A line across each box



indicate the median value. **(B)** Coomassie blue staining of SDS-PAGE with recombinant HIS-tagged wild-type (WT), D374K, S401A, R580E and L642T PADI2 proteins used for the citrullination assay.

**Table S1 (Related to Figure 3 and Figure S3).** GO Biological and molecular function analysis for differentially expressed after PADI2 knock down as shown in Figure 3A and Figure S5C. Significant ( $p < 0.05$ ).

**Table S2 (Related to Figure 3 and Figure S3).** List of cell cycle genes dependent and independent on R1810 RNAP2-CTD and PADI2 as indicated in **Figure 3H** and **Figure S3J**.

**Table S3 (Related to Figure 7).** List of interface residues of PADI2-CTD-R1810 peptide and binding energy. First and second column show the residue number and residue type respectively; third column indicates the sequence conservation among all PADI family members. Last column lists the Rosetta total energy for the given residue amongst the top 200 structural models.

**Table S4 (Related to the STAR method).** List of primers used for qPCRs.

**Movie S1 (Related to Figure 7).** A movie showing a 360-degree rotation of the lowest energy structural model of PADI2-CTD-R1810 peptide complex. PADI2 is shown in cartoon and surface representation (green) and R1810 RNAP2-CTD peptide in ribbon (magenta); selected amino acid for mutation studies R580, L642 and D374 and S401 are shown in orange and blue respectively.

**Movie S2 (Related to Figure 7).** A movie showing a 360-degree rotation of the lowest energy model of PADI3-CTD-R1810 peptide complex. PADI3 is shown in cartoon and surface representation (grey) and R1810 RNAP2-CTD peptide in ribbon (magenta).